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SUMMARY  
Arterial stiffness has been demonstrated to predict cardiovascular morbidity above and 
beyond traditional risk factors and can be estimated from measurements such as pulse wave 
velocity (PWV). Aortic PWV can be estimated from the carotid and femoral sites (CF-
PWV) by applanation tonometry and ultrasound. However, these methods only estimate a 
gross global burden, which may mitigate regional stiffness within the vasculature, and can 
be subjected to errors relating to uncertainties in estimating vessel length.  Magnetic 
resonance imaging (MRI) is an established clinical cardiovascular imaging modality which 
like ultrasound, has the advantage of being non-invasive and non-ionising. Whilst not 
typically part of a clinical cardiovascular examination, MRI sequences can be implemented 
to provide localised aortic PWV measurements directly from aortic sites. 
 
PWV derived by MRI (MR-PWV) is mostly confined to clinical research. It has been 
determined with high reproducibility and validated against invasive pressure measurements. 
MRI, as a technique, bears the potential to evaluate vascular anatomy and cardiac function 
in a single examination. For instance, it can provide aortic stiffness measure with a 
corresponding left ventricular assessment. Therefore, techniques such as MR-PWV 
warrants further investigation to see if it may prove beneficial in the detection of sub-
clinical disease or as an imaging biomarker of cardiovascular disease (CVD). 
 
In this research, MR-PWV was estimated using conventional methodology by determining 
the pulse wave transit time between two aortic sites, derived using MRI velocity encoded 
imaging of the aorta. When the technique was applied to a complicated diabetic population 
xix 
 
with and without symptomatic CVD in chapter 5, PWV yielded an important distinction 
between the groups (CVD with T2DM: 8.7 ± 2.8 ms
-1
, n =22, T2DM: 7.5 ± 2.3 ms
-1
, n =28, 
CVD without T2DM: 8.9 ± 3.6 ms
-1
, n =19 versus control 6.7 ± 1.8 ms
-1
, n =19, ANOVA P 
< 0.05). However, it did not show significant differences in patients with T2DM before 
onset of symptomatic CVD.  
 
This conventional method of PWV assessment was extended into a multi-site approach 
sampling several points along the aorta, with the hypothesis that aortic stiffness is a 
heterogeneous process that varies along the aortic length. This multi-site pulse wave 
velocity (MS-PWV) technique has been shown to increase the accuracy of PWV measures 
and was utilised in a subsequent study in chapter 6 and 7, involving healthy volunteers  and 
patients with peripheral vascular disease (PVD) , (healthy volunteers under 40 years: 4.5 ± 
0.7 ms
-1
, n = 22, older healthy volunteers over 40 years:  6.5  ± 1.5 ms
-1
, n=22 versus PVD 
patients 8.6 ± 3.1 ms
-1
, n = 26, P < 0.001).   
 
This thesis provides a novel insight into the process of arterial stiffening and subsequent 
cardiovascular health throughout different disease cohorts. It differs from current published 
work by examining MR-PWV in a heterogeneous diabetes and CVD population, while 
previous studies have solely examined either diabetic or CVD patients. Secondly, the use of 
MS-PWV has only been implemented in three previous studies to date; involving both a 
healthy population and cohort with Marfan syndrome. This research is the first to use this 
technique in PVD and the only study to derive MS-PWV in this population.  
 
xx 
 
In summary, PWV was shown to change with both the extent and severity of 
atherosclerosis and CVD, which is agreement with previous studies. This demonstrates that 
MR-PWV may be a useful research tool within the area of cardiovascular MRI and further 
work is needed to clinically define the potential impact of PWV.  
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PREFACE 
 
 
CVD is poised to become one of the most significant health problems worldwide. There is 
an inherent relationship between pathophysiology, biochemistry and structural remodelling 
with adverse cardiovascular outcomes. The research encompassed by this thesis involves 
the development and optimisation of cardiac imaging techniques in MRI and therefore 
detailed pathophysiology and biochemistry are outwit the scope of this thesis.  
 
The research study participants involved in this thesis have been part of larger research 
studies within the department of Cardiovascular and Diabetes Medicine and the University 
of Dundee. The Clinical Research Centre facilitates MRI imaging (Siemens Trio 3.0 Tesla 
MRI scanner) and is utilised in many local, national and European studies. These studies 
often apply MRI to answer research questions at the forefront of neuroimaging, 
angiography to cardiac imaging.  
 
Two substantial cardiovascular research studies carried out in the department include; The 
TASCFORCE Project: Tayside Screening for Risk of Cardiac Events and SUMMIT: 
Surrogate Markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes 
Tools.  Both projects have had assessments from both MRI and the Vascular and 
Inflammatory Unit. Simultaneously, a collection of other data has also been harvested from 
these studies including novel blood biomarkers and genomic screening.  
 
xxii 
 
One of the largest studies carried out in the department to date was the TASCFORCE 
study. All in all, over 1500 participants received a cardiac MRI scan as part of a larger 
screening program for to identify people with an increase risk of CVD. The participants 
were aged 40 and over, free from CVD and without an indication of preventative 
medication (e.g. statins). According to Adult Treatment Panel III (ATP III), they had less 
than a 20% 10 year risk of cardiovascular events. This cohort is referred to as ‘older healthy 
volunteers’ in Chapter 4 and Chapter 7.  
The SUMMIT study was part of the IMI funded European SUMMIT project. As part of the 
imaging work package 3, University of Dundee investigated a population of patients with 
T2DM, with and without evidence of CVD and non-diabetic control patients with and 
without evidence of CVD. The aim of the SUMMIT consortium was to identify markers 
that can predict the risks of developing diabetic micro and macrovascular complications 
including diabetic nephropathy, diabetic retinopathy and CVD. For this sub-study, the 
objective was to evaluate different MRI imaging techniques such as aortic PWV, LV 
cardiac function and whole body angiography. These results are presented in Chapter 5. 
 
This thesis is structured to provide an introduction to the cardiovascular system, with 
particular emphasis on the role of arterial stiffness and derivation of PWV using MRI 
techniques, followed by the project aims and hypothesis. The following chapter outlines the 
underlining theory of cardiac MRI and image formation. Subsequently, detailed 
descriptions of the equipment setup, image acquisition and analysis used will be discussed. 
The experimental chapters start from Chapter 4, where initial results for initial validation 
and optimisation of MR-PWV in this centre are presented. In Chapter 5, this MR-PWV 
xxiii 
 
technique is evaluated as part of the MRI protocol for SUMMIT. Subsequently, a 
modification of the conventional MR-PWV technique into a multi-site aortic assessment is 
investigated in Chapter 6 and Chapter 7. Further details of the experimental cohorts are 
outlined in Table 1-5.  
  
Part of the results presented in this thesis has also involved work from other fellow 
colleagues in the department. In Chapter 4, to test inter-observer reproducibility, flow 
quantification analysis was kindly repeated by Dr Jonathan Weir-Mc Call (JWC). Also, left 
ventricular segmentation analysis in Chapter 5 and Chapter 7 was completed by 
experienced cardiac researchers, Dr Shona Matthew (SM) and Dr Suzanne Duce (SD). 
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 CHAPTER 1
Background and Literature Review 
1.1 Development of the vascular network  
The early vasculature is initiated from the first passage of fluid ejected from the immature 
heart in human embryogenesis. The remodelling of the vascular network is initiated by the 
first passage of blood flow which triggers a signal cascade based on physical cues including 
both shear stress and circumferential stress. This also allows the identification of arterial 
and venous systems, angiogenesis and the regulation of genes through 
mechanotransduction (Hahn & Schwartz 2009). These processes ensure the future stability 
of the mature vascular network. The walls of large vessels are composed of vascular 
smooth muscles cells (SMCs) which lineage tracking studies have shown that vascular 
SMCs in different vessels have distinct embryonically origins (Majesky 2007).  
For instance, the largest conduct vessel, the aorta, begins its development during the third 
week of gestation (Kau et al. 2007) and shows heterogeneous embryonically differences 
along its length. The basal root is derived from secondary heart field, the arch and 
ascending aorta originates from the neural crest and the descending from the paraxial / 
somatic mesoderm (Cheung et al. 2012),  illustrated in Figure 1-1.   The regional diversity 
in SMC may in part contribute to susceptibility of site-localisation of vascular diseases such 
as vascular calcification, atherosclerosis or aortic aneurysms (Leroux-Berger et al. 2011; 
Haimovici 1991; Ruddy et al. 2008).  
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Figure 1-1 Embryological origins of the aortic smooth muscle cells (SMCs): The SMCs of the 
(i) aortic root originates from the lateral plate mesoderm, (ii) the ascending aorta is derived from the 
neural crest and (iii) the  descending aorta originates from the paraxial mesoderm. (Illustration 
adapted from Cheung et al., 2012) 
 
1.2 The Cardiovascular System 
After maturation of the vascular network, the cardiovascular system is established as a fluid 
transport system which allows the circulation and transportation of blood throughout the 
body. Its primary function is the transport of oxygen, nutrients and metabolites throughout 
the body, while removing waste such as carbon dioxide. The muscular structure of the heart 
is core to the cardiovascular system. Its primary role is to impart energy to the blood in 
order to generate and sustain adequate perfusion of organs. The heart can be structurally 
divided into two pumps connected in series, divided by the septum. The left side of the 
heart is composed of the left atrium and left ventricle separated by the mitral valve. 
Contraction of the left ventricle ejects blood though the aorta and is responsible all systemic 
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blood flow to organs, except the lungs (Figure 1-2). On the opposing side of the heart, the 
right atria and the right ventricle are divided by the tricuspid value. They feed into the 
pulmonary system allowing gaseous exchange to occur. This newly oxygenated blood 
returns to the left side of the heart and is distributed to other organs as described. 
 
 
Figure 1-2 Blood flow through the left heart chambers: The left chambers of the heart are 
responsible for expelling oxygen rich blood to all systemic organs, except the lungs. Adapted from 
(http://www.ceufast.com/). 
 
The heart’s rhythmic beat is controlled electrically and there are two basic phases in the 
cardiac cycle, systole and diastole (Figure 1-3). In systole, the heart undergoes contraction 
with electrical activation. In contrast, the heart relaxes in its diastole phase when the cardiac 
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myocytes are at their resting electrical state. These electrical potentials can be recorded in 
an electrocardiogram (ECG).  
 
 
Figure 1-3 Systolic and diastolic phases of the heart cycle: Ventricular changes through systole 
and diastole with its related pressure, volume and ECG changes. Where AP is the aortic pressure, 
LVP is the left ventricle pressure, and QRS complex of ECG. LVESV left ventricular end systolic 
volume. Adapted from (CVphysiology.com). 
 
Cardiac output can average approximately 4 to 6 litres of blood per minute at rest and is 
triggered by either intrinsic cardiac regulation in response to the volume flowing into the 
heart, or the control of heart rate and cardiac contractility by the autonomic nervous system.  
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1.2.1 Cardiac Indices  
There are a number of cardiac indices to assess cardiac function. Systolic indices try to 
quantify how well the LV pumps blood; the diastolic indices quantify how well the LV is 
being filled.  The indexes mainly focus on the left side of the heart (Lee et al. 2006). 
 Stroke volume (SV) is the difference between the end diastolic volume (EDV) and 
end systolic volume (ESV) as shown in Equation 1-1.  
 
 
           1-1 
 Ejection fraction (EF) represents the percentage volumetric measure of blood 
ejected from the heart (%) given to Equation 1-2. 
 
 
   
       
   
       
  
   
      1-2 
 The cardiac output (CO) is the net forward flow of blood per minute measured as 
millilitres per minute, calculated by Equation 1-3.  
 
 
         1-3 
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1.3 Normal Haemodynamics of the Cardiovascular System 
 
Homeostasis of haemodynamics involves the regulation of the blood circulation to provide 
adequate blood flow, maintaining optimal organ perfusion and tissue function. The 
circulatory system is composed of various structural components; the heart provides the key 
phasic pressure changes by the delivery of a bolus of blood into the aorta. The elastic 
characteristics of the aorta and large arteries allow for rapid expansion and recoil, pre and 
post ejection of the heart.  
 
The ejected blood enters the arterial bed in systole and continues onwards during diastole 
under the ‘Windlkessel effect’, which refers to the compliance of the aorta with the arterial 
pressure wave. The systemic vascular resistance is determined by the small arterioles, pre-
capillary arterioles and any changes in the viscosity of the blood. The post-capillary 
resistant vessels drain into the larger venules and veins which are termed the capacitance 
vessels. The dissipation of pressure between all these vessels is illustrated in Figure 1-4. 
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Figure 1-4 Pressure and flow velocity profile in the systemic circulation: The arterial part of the 
circulation is characterised by high pulsatile pressure and high flow velocity. This system changes 
to a low pressure and low velocity, filtering into the venous system. The lowest point is at the point 
with greatest vascular resistance in the capillaries beds. Adapted from (Bell et al., 2008). 
 
Through different vascular beds, the system changes from a high to low pressure system. 
The dotted blue line in Figure 1-4 is the average velocity of the blood flow that is 
proportional to the pressure (P) difference along a vessel (Equation 1-4). 
 
 
     1-4 
The flow rate (Q) is determined by the average velocity (  ̅) (distance/time) of the blood by 
the cross area (A) of the vessel it is flowing through, where A=π.r
2
, (Equation 1-5). 
 
 
   ̅   1-5 
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According to the principle of continuity, flow rate in equals the flow rate out, therefore as 
the velocity of a fluid increases, the area decreases proportionally. This is illustrated in 
Figure 1-5.  
 
Figure 1-5 Principle of continuity of flow rate: Illustration of the principle of continuity: 
and the relationship between area (A), vessel diameter (ø) velocity (v) and flow rate (Q).  
 
Normal aortic blood velocity has been shown to be independent of sex, body surface area 
(BSA) and blood pressure but it progressively decreases with age. In a study by Mowat et 
al. (1983), normal ranges of blood velocity was found to be between 52 and 152 cm.s
-1
 in a 
healthy population (aged between 15 to 80 years), Figure 1-6. It shows an age dependant 
relationship, for example the mean peak velocity at age 70 has been shown to be 55% of 
that of age 20. 
 
(In this thesis, flow rate has been used but it is equally acceptable to use average velocity or 
pressure for estimation of PWV.) 
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.  
Figure 1-6 Relationship between aortic blood velocity and age in males and females: Mowat et 
al (1983) shows that peak aortic blood velocity falls progressively with increasing age (r = 0.7, P < 
0.005), where the closed dots represent males (n = 61), and the open dots represents females (n = 
79). Adapted from (Mowat et al. 1983).  
1.3.1 Blood Pressure and Pulse Pressure  
The arterial pressure of the systemic circulatory system has been used as an indicator of 
human health for over a century (Muller et al. 1989). Measurement of pressure can be 
divided into systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial 
pressure (MAP) and pulse pressure (component of SBP and DBP). There is a well-
established association between either SBP or DBP and the risk of CVD. Blood pressure is 
composed of both a pulsatile and a steady component. The pulsatile part, pulse pressure, 
represents the variation between SBP and DBP and is affected by left ventricular ejection 
fraction, large artery stiffness, heart rate and early pulse wave reflection.  The steady 
component is represented by mean arterial pressure, and is a function of left ventricle 
contractility, heart rate, and vascular resistance (Franklin et al. 1997). 
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1.4  Pathophysiology of Cardiovascular Disease  
Any disease or irregularity effecting normal function of the cardiovascular system is 
classified as CVD. It usually stems from vascular dysfunction and can manifest itself 
causing either structural abnormalities such as hypertrophy, cardiomyopathy, heart failure, 
ischaemic heart disease or vascular dysfunction. The causes of CVD are multi-factorial 
with risk factors being a combination of either behavioural, metabolic and other factors 
such as aging, gender and genetic polymorphism. In particular, high blood pressure, blood 
glucose, serum cholesterol and body mass index (BMI) have been identified as key 
mortality cardiometabolic risk factors in CVD, diabetes and chronic kidney disease (Lancet 
2014).  
The development of atherosclerosis, high blood pressure or thrombosis have been shown to 
be the principle causes of CVD events (Hackam & Anand 2003; Vasan et al. 2001). It is 
now recognised that CVD is part of a family of atherothrombotic diseases and patients who 
survive one major CVD event such as myocardial infarction or stroke are at a greater risk of 
subsequent adverse events and death (Adams et al. 2003). 
 
In the past few decades, major improvements have been made in the treatment of certain 
types of CVD e.g. statin treatment and stent implantation in coronary and peripheral artery 
disease, resulting in a declining mortality rate (Smith et al. 2006). However, more treatment 
options are needed and improving diagnosis is crucial, particularly at the earlier stages of 
disease.  
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1.5 Epidemiology of Cardiovascular Disease 
CVD is the leading cause of global mortality (17 million deaths, total 48% global burden, 
WHO, 2011), with diabetes contributing to an additional 1.3 million deaths. It has been 
projected that this will increase to 23.3 million by 2030 (WHO, 2011, Mathers 2006) and 
CVD is estimated to remain the single leading cause of death. Demonstrating the global 
need for identifying individuals at risk of developing cardiovascular complications early 
and providing therapeutic measures in order to prevent or reduce the incapacitating 
consequences associated with CVD.   
1.6 Role of Risk Factors in Cardiovascular Disease  
CVD has a long asymptomatic period which provides a possible opportunity for early 
preventive intervention. Risk factors for the development of atherosclerotic disease have 
been well established in evidence based medicine guidelines such as the American Heart 
Association (AHA) and the American College of Cardiology (ACC) (Greenland et al. 
2010). Independent CVD risk factors include an unfavourable level of blood lipids, blood 
pressure, aging, body weight and body fat distribution and composition, smoking diabetes 
and genetic predisposition (Lloyd-Jones et al. 2006; Vinereanu 2006). Strategies for 
medical management revolve around identification, surveillance and management of risk 
factors, in particular modifiable factors (as shown in Table 1-1). 
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Table 1-1 Risk factors that effect CVD: Identification of key risk factors is important for CVD 
intervention. 
Major modifiable risk factors 
 
o High blood pressure 
o Abnormal blood lipids 
o Tobacco use 
o Physical inactivity 
o Obesity 
o Unhealthy diet 
o Diabetes mellitus 
Other modifiable risk factors 
 
o Low socioeconomic status  
o Mental ill health (depression) 
o Psychosocial stress 
o Heavy alcohol use 
o Use of certain medication 
o Apolipoproteins  
Non-modifiable risk factors 
 
o Age 
o Heredity or family history 
o Gender 
o Ethnicity 
Novel risk factors 
 
o Excess homocysteine 
o Inflammatory markers (e.g. C- reactive 
protein) 
o Abnormal blood coagulation (elevated 
blood levels of fibrinogen) 
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Preventive efforts target each risk factor, if left untreated these have the potential to 
develop into CVD. Risk factors are seldomly seen in isolation, and global risk assessment 
based on the summation of all major risk factors can be clinically useful. They can help 
with the identification of high risk patients, heighten motivation to adhere to risk reduction 
therapies and allow modification of the intensity of risk reduction efforts (Grundy et al. 
1999). These multivariate risk functions have been derived from several large cohort 
studies and randomised controlled trials to form the basis of predictive function and risk 
scores. Many risk factors have been derived from the Framingham heart study, and have 
been subsequently adapted for assessing an individual absolute risk in primary care (Lloyd-
Jones et al. 2004). These prevention methods have shown a significant impact on reducing 
CVD burden and can improve patient outcomes.  
 
Although useful, the identification of traditional risk factors does not account for the 
entirety of CVD risk and there are many people that do not fit the traditional definition of 
“at risk”. Risk models also are limited to showing either low risk or high risk individual, 
falling short on middle tier or intermediate risk. For instance, Futterman & Lemberg (1998) 
found that more than 50% of people diagnosed with chronic heart disease lack any of the 
conventional risk factors. To that end, there is still a need to identify new biomarkers in 
order to find ways of identifying those individuals at risk in an attempt to alter their 
prognostic outcomes (Montgomery & Brown 2013). 
 
In pursuit of refining CVD risk prediction, recent studies have highlighted the potential 
identification of new novel biomarkers including carotid intima-media thickness 
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(cIMT)(Bots et al. 2014), Brain natriuretic peptide (BNP), C-reactive protein (C-RP) and a 
variety of genetic variants. Interesting to date, the majority of these markers add little to the 
existing risk prediction estimates such as that derived from Framingham Heart Study 
(Wang et al. 2006; Bots et al. 2014; Ben-Shlomo et al. 2014; Goff et al. 2014). 
 
1.6.1 Age Related Changes in Vascular Function 
The mechanistic explanation of aging in the cardiovascular system is believed to be a result 
of cumulative damage brought on by various physiological and physical insults. Ageing has 
been shown to contribute to major structural changes in large elastic arteries and increases 
in wall thickening are associated with age. As a consequence of this remodelling, there is a 
reduction of arterial compliance and vessel stiffness increases. Other factors such as 
increased collagen, reduced elastin and calcification further affect this process.  
 
As large arteries become stiffer, changes in pressures within the cardiovascular system also 
occur. There is an increase in systolic arterial pressure, a decrease in diastolic pressure and 
a widening of pulse pressure (PP). This pattern of changes in the vasculature with respect to 
indices of pressure differs from what is seen with hypertension, for which there is a total 
increase of peripheral resistance (effecting both SBP and DBP equally). 
 
Following this, data from population studies (Franklin & Wong 2013) have indicated that 
PP may be more important measure of large artery stiffness in ageing populations. The 
Framingham heart study found a progressive decrease in DBP and a rise in SBP with 
ageing causing a widening of PP, particularly in the elderly (Franklin et al. 1999).  Other 
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elastic indexes (as further described in Table 1-1) have the ability to reflect vascular 
stiffening as it is determined by a stress strain relationship of the vascular wall.  
 
A portion of the arterial stiffening that happens with ageing can be attributed to a reduction 
in endothelial cell function, which normally opposes contraction of the underlying vascular 
smooth muscle. It has been shown with ageing, there is a reduction of nitric oxide (NO) 
produced by the endothelial cells. NO is produced from the oxidation of L-arginine by 
endothelial nitric oxide synthase (eNOS). A full mechanistic breakdown of this process is 
outside the scope of this thesis, however Davignon & Ganz (2004) provides a summary of 
the process.  
 
1.6.2 Endothelial Dysfunction and Atherosclerosis  
When endothelial cells become dysfunctional, vascular smooth muscle cells (SMC) 
relaxation is impaired and its phenotype is shifted to a synthetic form that promotes growth, 
pro-inflammatory responses and thrombosis. Eventually these functional defects result in 
structural changes to the arterial wall with SMC proliferation. This then leads to favourable 
conditions for platelet and leukocyte activation and adhesion as well as cytokines that 
increase permeability to oxidised lipoproteins and inflammatory mediators. Hence, 
endothelial dysfunction is pivotal to early stages of atherogenesis as shown in Figure 1-7 
and has been linked to levels of vascular disease risk factors (Della Rocca & Pepine 2010).  
In later stages of atherosclerosis, fatty fibrous lesions or plaques are evident within the 
vessel walls. Atherosclerosis is a chronic inflammatory disorder and is associated with 
CVD and is exacerbated by risk factors such as central abdominal obesity, insulin 
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resistance, hypertension and type 2 diabetes mellitus (Burnett 2004). The balance between 
atherosclerotic plaque stability and instability determines plaque fate and risk of adverse 
clinical events. In recent years, a significant improvement of outcomes have stemmed from 
therapies that reduce the level of circulating cholesterol (Scott 2004).   
 
 
Figure 1-7 Atherosclerosis timeline: The underlying role of endothelial dysfunction is shown in 
the progression of atherosclerosis from initial lesion to complicated lesion. Adapted from (Pepine et 
al. 1998). 
 
1.6.3 Diabetes Mellitus  
CVD is the major risk factor and cause of morbidity and mortality for patients with diabetes 
being first described as a major risk factor by Haffner et al. (1998), (Figure 1-8). Compared 
to the general population, patients with diabetes have a four times greater incidence of 
CHD and a two to four fold higher risk of cardiovascular event.  
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Figure 1-8 Kaplan–Meier estimates of the probability of death from coronary heart disease: 
Percentage survival in the Haftner study for 1059 subjects with diabetes and 1378 non-diabetic 
subjects with and without prior history of myocardial infarction. Adapted from (Haftner et al, 
1998). 
 
The American Diabetes Association (ADA) have classified diabetes into four subgroups 
(ADA 2008); Type-1 diabetes mellitus (T1DM) which results from the β-cell destruction, 
usually leading to the absolute insulin deficiency, Type-2 diabetes mellitus (T2DM) is 
developed from a progressive insulin secretory defect on the background of insulin 
resistance, gestational diabetes mellitus where diabetes is diagnosed during pregnancy and 
other specific types of diabetes due to other causes such as genetic defects in insulin action 
or defects from β-cell function, diseases of the exocrine pancreas e.g. cystic fibrosis and 
drug or chemical induced e.g. treatment of acquired immunodeficiency syndrome or after 
organ transplantation. 
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In this thesis, patients with T2DM with and without cardiovascular complications, the other 
classifications of diabetes have not been detailed and are outside the scope of this thesis. 
Both T2DM and CVD share similar characteristics as the occurrence increases with age, 
obesity, both have an adverse lipid profile and both can be reduced by lifestyle 
modification. In recent years, there has also been new focus on measurement of ‘non-
traditional’ risk factors such as inflammatory markers, advanced glycosylation end products 
(AGEs), cardiac autonomic neuropathy and polymorphic genes to investigate if they may 
provide novel insights into mechanisms linking diabetes and CVD.  
 
1.6.4 Hypertension 
Hypertension is defined as a chronic increase of arterial blood pressure and is associated 
with adverse outcomes. It is a physical symptom that increases the after load on the heart 
and stresses the coronary arteries which progresses to an increased mean arterial pressures 
and increase in arterial diameter and stiffness. Initially, at low pressures the elastin 
components of the vessel wall is able to endure the increased stress. However, as the 
pressure increases, the arterial wall recruits mores collagen fibres to compensate for 
changes in wall stress and thus resulting in larger, stiffer arteries.  Over a period of time, 
hypertension accelerates arterial degeneration in the arterial wall. It has been shown to be 
associated with increased risk of CHD, heart failure, and other CVD complication.  Overall 
the prevalence of hypertension appears to be around 30–45% of the general population, 
with a linear increase with ageing (Mancia et al. 2014).  
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1.6.5 Coronary Heart Disease 
Coronary heart disease (CHD) is the most common type of cardiovascular complications 
and is responsible for one out of every five deaths (Chilton 2004). CHD is characterised by 
atherosclerosis in the epicardial coronary arteries. The atherosclerotic plaques progressively 
narrow the coronary artery lumen and cause impairment of antegrade myocardial blood 
flow (Libby & Theroux 2005). Epidemiological studies and long term outcome trials have 
established a link between plasma lipids and CHD, with lowering low density lipoprotein 
(LDL) significantly reducing major coronary events (Nissen et al. 2004). 
1.6.6 Cerebrovascular Disease 
Cerebrovascular disease is associated with associated with vascular disease and is caused 
by an impaired supply of blood to the brain resulting in loss of brain function. The severity 
of stroke can be classified as major stroke, minor stroke and transient ischaemic attack 
(TIA), also referred to as a mini stroke. Following a period of cerebral ischemia or 
haemorrhage, long-term or permanent neurological symptoms may arise and result in 
disability. Minor stroke refers shorter term effects, usually lasting less than 24 hours and 
the symptoms are considered mild and non-disabling (Slark & Sharma 2009).    
1.6.7 Peripheral Vascular Disease  
Peripheral vascular disease (PVD) is a disease of the lower extremities as a result of 
atherosclerotic occlusive disease. It has been recently linked as an independent risk factor 
for myocardial infarction and cerebrovascular disease with the incidence of PVD in the 
general population from 3- 10% in under 70 years, to 15- 20% in people above 70 years. 
Typical presentation of PVD is intermittent claudication, however this has been shown to 
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only reflect 10% of patients and approximately 40% of patients are asymptomatic 
(Schirmang et al. 2009; Hennion & Siano 2013).  
 
1.7 Arterial Stiffness 
.  
Arterial stiffness has been shown to be a strong predictor of cardiovascular morbidity and 
mortality. It is a reflection of the degree of arterial ageing and can be defined as the ability 
of the artery to expand and contact during cardiac pulsation and relaxation (Kawasaki et al. 
1987). Arterial stiffness is a dynamic parameter that can be regulated by changes in the 
structural components of the vessel wall such as collagen, elastin and endothelial cells, but 
also by vascular smooth muscle tone and circulatory factors including NO and endothelin-1 
(Wilkinson & McEniery 2004). 
 
As previously mention, there is a dependent relationship between elasticity and pressure of 
the arterial system. Linking of these factors was first described by Bramwell and Hill 
(1922) in Proceedings of the Royal Society of London; 
 
“The amount of energy expended by the heart … is … proportional to the pressure 
developed; hence the amount of energy which the heart has to expend per beat, 
other things being equal, varies … with the elasticity of the arterial system” 
 
Bramwell and Hill used their observation of haemodynamic measures to provide alternative 
measures of arterial stiffness, which will be described later in 1.8.1. 
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These observations have been refined into several elastic indexes, incorporate pressure, 
distance and diameter change to estimate arterial compliance and distensibility. They are 
often used to describe arterial stiffness and are further detailed in Table 1-2. Arterial 
compliance can be defined as the change in the vessel diameter in response to blood 
pressure and has an effect on contractility, blood flow dynamics and perfusion. 
Distensibility is the arterial compliance relative to the inner diameter of the artery, 
providing normalisation for vessels of different sizes.  
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Table 1-2 Indices of arterial stiffness. 
Term Definition Formula Units 
Methods of 
measurement 
Elastic modulus 
The pressure change required for 
theoretical 100% stretch 
from resting diameter 
(ΔPxD)/ΔD mmHg 
Ultrasound 
MRI 
Young’s modulus Elastic modulus per unit area (ΔP x D)/(ΔDxh) 
mmHg/c
m 
Ultrasound 
MRI 
Arterial 
Distensibility 
Relative change in diameter (or 
area) for a given pressure change; 
inverse of elastic modulus 
ΔD/(ΔPxD) mmHg
-1
 
Ultrasound 
MRI 
Arterial 
Compliance 
Absolute diameter (or area) 
change for a given pressure step 
 
DD/DP 
cm2/mm
Hg 
or 
cm/mmH
g 
Ultrasound 
MRI 
Pulse Wave 
Velocity 
Velocity of travel of the pulse 
along a length of artery 
Distance/Δt cm/s 
Pressure waveform 
Volume waveform 
Ultrasound 
MRI 
Augmentation 
Index 
The difference between the 
second and first systolic peaks as 
a percentage of pulse pressure 
  
Pressure 
Waveform 
Stiffness Index 
(β) 
Ratio of ln (systolic/diastolic 
pressures) to (relative change in 
diameter) 
  
         
          
  Ultrasound 
Capacitative 
Compliance 
Relationship between pressure 
change and volume change in 
the arteries during the exponential 
component of diastolic 
pressure decay 
ΔV/ΔP 
cm
3
 
/mmHg 
Pressure waveform 
Oscillatory 
Compliance 
Relationship between oscillating 
pressure change and oscillating 
volume change around the 
exponential pressure decay during 
diastole 
ΔV/ΔP 
cm
3
 
/mmHg 
Pressure waveform 
Abbreviations: P: pressure, D: diameter, V: volume, h: wall thickness, t: time, v: velocity. 
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The haemodynamic wall shear stress (WSS) is a result of innermost intima vessel layer is 
exposed to both wall stress caused by pulsating blood pressure and WSS caused by 
pulsatile blood flow (Qian et al. 2014).  In clinical practice, these changes of blood flow 
dynamics have been used to diagnosis target and an important issue in the development of 
CVD. Studies have also shown that although ageing is the strongest predictor of arterial 
stiffness, the degree of stiffness can be accelerated by various risk factors such as 
hypertension, smoking, high salt intake, dyslipidemia, diabetes mellitus and biomarkers 
such as high sensitivity CRP (hs-CRP) (Laurent, Cockcroft, Bortel, et al. 2006). 
 
1.8 Pulse Wave Velocity  
Aortic PWV represents the speed at which the pulse wave propagates through the arterial 
system to the peripheral vasculature. The rate of propagation reflects on the viscoelastic 
properties of the artery with PWV being an index of regional arterial stiffness (Laurent, 
Cockcroft, Bortel, et al. 2006). Increased arterial stiffness has been shown to be 
cardiovascular risk factor independent of classical risk factors and has been included in the 
European society of hypertension guidelines (Mancia et al. 2007). It has been generally 
agreed that many cardiovascular disorders are associated with the rigidity of the arterial 
wall due to atherosclerosis. PWV has been shown to provide CVD risk predication 
independently of standard risk factors such as pulse pressure, blood pressures and 
glycaemic control (Cardoso et al. 2013). This predicative power of CVD mortality of aortic 
PWV and pulse pressure is shown in Figure 1-9.  
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Figure 1-9 Relative hazard ratios for aortic PWV, office PP and 24h PP: Hanson T et al (2006) 
shows the composite cardiovascular end point of aortic PWV, office pulse pressure, and 24 hour 
pulse pressure with white circles indicating unadjusted, and black circle adjusted for age and sex. 
Reproduced from (Hansen et al. 2006).  
 
It has also been found adding PWV, just like pulse pressure and number of carotid or 
femoral atherosclerotic plaques, to the Framingham risk score improves the accuracy of the 
risk prediction model in apparently healthy subjects (Bérard et al. 2013)  
 
1.8.1 Theoretical Model: Derivation of PWV  
Elastic and hydraulic theory was first established by early physicists such as Young (1808), 
Poisuille (1840), Moens and Korteweg (1878). Pulse transit time (PTT) is the time it takes 
the pulse waveform to propagate through the length of the arterial tree. The pulse pressure 
waveform forms the ejection of blood from the left ventricle and moves with velocity much 
greater than the forward movement of blood.  
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The first principles of the velocity of the pulse wave through the arterial tree is derived 
from Newton’s second law of motion (Young 1808). Later, the relationship between the 
pulse wave and the elasticity of a thin walled elastic tube filled with an incompressible fluid 
is expressed by Moens-Korteweg Equation 1-6. This directly relates PWV and arterial wall 
stiffness, where E: Young’s modulus of arterial wall, h: arterial wall thickness, r: arterial 
radius at end diastole and ρ: blood density.  
 
    √
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The assumptions being; there is no or insignificant change in vessel area or wall thickness 
and that dv (dr
-1
) dx. dt is small to the point of insignificant. From this equation we can see 
that PWV is related to the square root of Young’s modulus of elasticity (E). Therefore 
measuring PWV leads to an estimation of stiffness of the tube. Higher velocities correspond 
to higher arterial stiffness. The blood density of a person should stay fairly constant. The 
other two parameters h and r may be estimated with imaging techniques. In the progression 
of atherosclerosis, as the vessel wall thickness (h) increases, the vessel radius decreases (r) 
and therefore will be indicated by an increase PWV.    
1.8.2 Measurement of PWV 
The mechanical behaviour of large arteries caused some difficulties to the technical and 
theoretical aspects. Firstly, arteries have marked anisotropy and exhibit non-linear 
viscoelastic properties.  Secondly, no single arterial segment has identical viscoelastic 
properties and has a powerful adaptive capability (Nichols WW 2011). Adaptions to the 
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Windkessel Model or the arterial wave propagation, has allowed the clinical application of 
aortic PWV (Safar 2006) 
 
The first method that can estimate PWV is by using the velocity of the forward travelling 
wave. The PWV is defined as the velocity of an arterial wall disturbance towards the 
periphery and rate of contraction of the ventricle. It can be determined by measuring the 
time delay of the flow or pressure waveforms, Δt, between two sites of a known distance 
Δx, Equation 1-7 .  
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This definition holds true under the assumptions that no wave reflections occur as the 
transmission for the pressure pulse as a sum of incident and reflected waves does not 
represents true PWV. The wave speed is measured from the wave characteristics such as 
the foot of the wave, upslope of the wave or the mid-point of each wave at two locations. 
Equation 1-7 used in this thesis as MRI can provide a direct measure of blood velocity 
ejected out at different aortic sites.  
 
The second method of estimating PWV is by two simultaneously measured pressure waves. 
This method utilises the feature of the arterial waveform that occurs during late diastole and 
early systole, where there is none or minimal interference of the incident pressure wave by 
the pressure wave (Bramwell & Hill 1922). The time difference between these two waves is 
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generally estimated by the foot-foot method, under the implicit assumption that the foot of 
the wave is free of reflections. This measurement can be obtained using invasive pressure 
catheters or non-invasively by pressure tonometers placed on the skin, where the sites have 
a known distance apart.  
 
PWV can also be estimated in terms of pressure and flow by the Bramhill & Hill  model 
(Bramwell & Hill 1922) derived from Moens-Kortweg equation, where the wave speed is 
in terms of dV/VdP. The Bramhill &Hill equation for pressure and flow in Equation 1-8. 
 
    √
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This alternative method can be estimated where pressure can be measured and flow and 
arterial dimensions measured with A or M-mode ultrasound or Doppler measurement of 
flow. 
 
1.8.3 Gold Standard, Clinical Standard and MR Derived PWV 
As previously mentioned, there are several methods and devices that can measure PWV 
both regionally and locally. Although not common, gold standard PWV derivation is the 
invasive pressure wire method. While this method can give highly accurate measurements 
of PWV, the invasiveness involved restricts its use to animal studies or patients undergoing 
cardiac catherisation.  
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The most common and widespread methodology is the non-invasive carotid-femoral 
tomography or ultrasound method. Due to its low cost and non-invasiveness, it is thought to 
be a clinically viable method. However these methods only provide a gross global PWV 
from the carotid and femoral arteries and may mitigate regional stiffness within the 
vasculature.  
MR-PWV can also be used with the advantage that a local aortic measure can be made and 
there is no geometric assumptions needed, and additionally it can be added to a standard 
cardiac examination. However, it is still confounded to research studies and has limitations 
such as expense and is unsuitable for patients with contraindications (e.g. implants, 
pacemakers or claustrophobia).  Nonetheless, there is still a need to determine if it can add 
more prognostic value than the regional CF-PWV method, particularly as an early surrogate 
marker of macrovascular changes and CVD.  
1.8.4  Carotid-Femoral PWV 
In CF-PWV, a tonometer device is placed on the skin over both the carotid and femoral 
arteries. A pressure waveform is recorded at both locations and the temporal shift is 
estimated between the carotid and the femoral pressure wave times as transit time, which 
predominantly the time to foot method. The distance measuring between these two sites are 
calculated with a tape measure by either two methods. Either by measuring the direct 
distance between the carotid and femoral arteries or by taking the difference between the 
distance from the sternal notch to the femoral artery and the sternal notch to the carotid 
artery. This distance is divided by the transit time to compute PWV.  
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A major source of error in this setup configuration is the accuracy of the distance 
measurement and has been reported to cause errors up to 30% (Vermeersch et al. 2010; 
Salvi et al. 2008), particularly in patients with large BMI (> 35 kg.m
2
) (Joly et al. 2009) 
However, there has equations proposed to correct for inaccuracies in these distance 
measurements (Huybrechts et al. 2011; Vermeersch et al. 2009).  
 
1.8.5 MRI and PWV  
The measurement of MR-PWV using conventional phase contrast (PC) MRI is recognised 
as a standard technique to assess arterial stiffness by measuring the arrival times of blood 
velocity waveforms. Conventional PC-MRI requires the acquisition of two sets of complex 
images with different velocity sensitivities or encodings. 
 
The aortic PWV is commonly calculated in MRI as the ratio between the distance 
separating two locations of the aorta and the transit time needed for the flow wave to cover 
this distance. Although the estimation of the distance can be quite easily calculated from an 
abdominal image of the aorta, the determination of the transit time is somewhat more 
difficult. Indeed, due to the wave reflections and damping by aortic wall, the profile of the 
velocity waves extracted from PC-MRI data can change and bias the transit time 
measurement. Several studies described different methods for the aortic PWV estimation 
using MRI. However, the main difference between the proposed methods was the 
determination of the transit time, and even if the foot-to-foot method is commonly used to 
calculate the transit time there is no standardised method for the PWV determination. 
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1.8.6 Predicative Power of Carotid-Femoral PWV 
A range of reference values for CF-PWV have been reported in the literature. A large 
multi-centre study measured CF-PWV with tonometry and reported a normal range of 6 ms
-
1
 in healthy individuals under 30 years and up to 10ms
-1
 in individuals > 70 years of age, 
independent of blood pressure. As part of a Framingham heart study, Mitchell et al. 2010 
investigated the prognostic value of CF-PWV in CVD; the results are shown in Figure 
1-10.  
 
 
Figure 1-10 Kaplan–Meier plot of cumulative probability of a first major CVD event:  
Participants from the Framingham heart study were grouped according to quartiles of CF-PWV to 
investigate its prognostic value for CVD events. Reproduced from (Mitchell et al. 2010). 
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Until recently, CF-PWV has been confined to research studies, however it is gaining 
increasing recognition of its potential prognostic value through large population and 
longitudinal studies (Vlachopoulos 2010). A recent meta-analysis of 17,635 subjects by 
Ben-Shlomo et al. (2014), has shown with consideration of CF-PWV that include standard 
risk factors, it can better identify high-risk CVD populations. Collectively, these studies can 
provide a strong evidence base for a potential risk stratification reference ranges.  
Unfortunately, there is a discrepancy between CF-PWV and phase contrast MR-PWV value 
ranges so they are not directly comparable. In general, CF-PWV are higher (~2 ms
-1
) than 
MR derived values. The reason for this is likely to be multifactorial. The difference could 
be caused by the lower temporal resolution of MR and or the more focal nature of the MR 
based measurements of the aorta compared to the more global nature of the carotid and 
femoral vascular beds. Furthermore, one of the key differences between these techniques is 
the accuracy of the distance which may another contributing factor. The initial study that 
used MRI to detect early arterial disease via PWV was discussed by Mohiaddin (Mohiaddin 
& Longmore 1989). However, renewed interest in MR-PWV occurred in later years when 
faster and more robust MR sequences became commercially available. 
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1.8.7 Aortic PWV in MRI studies  
MRI derived PWV has shown good agreement with invasive intra-aortic pressure 
measurements (Grotenhuis et al. 2009) and has been shown to correlate well with the ‘gold-
standard’ CF-PWV (via tomography method) (Joly et al. 2009). However, the ‘normal 
ranges’ of PWV have been found to be higher in CF-PWV estimation methods than in MR-
PWV. To date, the majority of MR-PWV studies have been single centre with small sample 
cohorts, but in general normal ranges for a healthy population is of the range of 4 – 6 ms
-1
 
(Wentland et al. 2014). To date, there has been no systematic review or meta-analysis 
generated on a collective view of normal ranges in MR publications. In order to provide 
baseline PWV comparison for later result chapters, a table of all MR studies (last updated 
search Pubmed July 2014) has been compiled.  
Using the Preferred Reporting Items of Systematic reviews and Meta-Analyses (PRISMA) 
method (Liberati et al. 2009), 422 articles were identified and screened by abstract. 
Seventy-two articles were further analysed by full paper, leaving a remainder of 23 
applicable studies with comparable PWV techniques. A summary of all the studies is 
shown in Figure 1-11.  
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Figure 1-11 Summary of comparable MR-PWV studies (n = 23): Most studies have used a 
healthy population as a comparator to a patient group. Abbreviations: CHD: Coronary Heart 
Disease, T1DM: Type-1 Diabetes Mellitus T2DM: Type-2 Diabetes Mellitus, HT: Hypertension, 
YHP: Young Healthy Population, OHP: Older Healthy Population and MAP: Mixed Age 
Population. 
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1.8.8 Healthy Range for MR-PWV 
To obtain ranges for healthy participants, data was extracted from the 22 out of the 23 
selected MR-PWV papers. They were further divided into the following subheadings; under 
40 years (participants were between 15 to 39 years, weighted average of 29 years), over 40 
years (range between 40 and 76 years, weighted average of 54 years) and a mixed age 
group (MAP) (range between 18 to 70 years), where it was not possible to break down 
values.  
The results of the described analysis are displayed in Table 1-3 for the entire aorta and 
graphically displayed in Figure 1-12.  
Table 1-3 Summary of MR-PWV ranges for healthy population: Average PWV values are 
given for young healthy population (YHP, < 40 years), older healthy population (OHP, > 40 years) 
and a mixed aged population (MAP, 18 to 70 years old) from 26 studies.  
Type of 
participants 
No of 
Studies 
Av no of 
participants 
per study 
Total number 
of patients 
Age Range 
Average 
PWV (ms
-1
) 
YHP 17 37  ± 40 633 < 40 years 
4.7 ± 0.6 
OHP 4 24  ± 20 98 > 40 years 
6.8 ± 0.9 
MAP 5 23 ± 10 117 18 – 70 years 
5.9 ± 1.3 
1.8.9 Patient Ranges for MR-PWV 
To obtain ranges for different patient population, data was extracted from the 13 out of the 
25 selected MR-PWV papers (15 different cohorts of patients).  The results are displayed in 
Table 1-1 and Figure 1-13 for the PWV of the entire aorta. From out analysis of the patient 
cohorts, there has been three studies that have included CVD patients (CHD) (Grotenhuis et 
al. 2009; Yu et al. 2006; Lee et al. 2007a) and one study with T2DM and CHD (Lee et al. 
2007a) with T2DM (van der Meer et al. 2007).  
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Table 1-4 MR-PWV ranges for patient populations: PWV values as collated from previous 
studies.  
Type of participants 
Total 
number of 
patients 
Age Range 
(years) 
No of 
Studies 
Av no of 
participants per 
study 
Average PWV 
(ms
-1
) 
Atherosclerosis (with 
prior evidence of stoke) 
25 66 ± 8 1 25 
7.0  ± 0.24 
CHD 42 63 ± 7 3 14 
8.0 ± 2.8 
CHD + T2DM 17 65 ± 2 1 17 
8.8 ± 0.8 
Hypertension 31 49 ± 14 1 31 
7.3 ± 1.2 
Hypertension + T1DM 28 50 ± 6 1 28 
7.3 ± 1.3 
Marfan Syndrome 52 36 ± 15 3 17 
6.2 ± 1.5 
Obese (>35 BMI) 50 43 ± 9 1 50 
5.7 ± 1.5 
Young smokers 22 31 ± 2 1 22 
5.2 ± 0.3 
T1DM 20 48 ± 6 1 20 
5.9 ± 1.2 
T2DM 14 55 ± 8 1 14 
6.8 ± 1.6 
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Figure 1-12 Dot and box plot of the mean PWV in healthy populations: A summary of mean 
PWV values of MRI studies for young healthy population (YHP), older healthy population (OHP) 
and mixed age population (MAP). 
 
 
 
 
Figure 1-13 Dot and box plot of the mean PWV in each of patient populations A summary of 
mean PWV values of MRI studies for atherosclerosis, coronary heart disease (CHD), type-2 
diabetes mellitus (T2DM), hypertension (HT), marfan syndrome, obese population and smoking.  
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1.9 Chapter Summary 
This chapter highlights the asymptomatic period of CVD provides an opportunity for early 
prevention and intervention. Established risk prediction models can identify patients at high 
risk but studies have also shown this may only be effective in 50% of CHD patients. Thus 
the search for other predictive markers is therefore needed. The scope of this research is to 
investigate whether PWV, as derived by MRI, can show an independent statistical 
association with disease risk. A major limitation was uncovered while reviewing literature, 
highlighting the need of MR-PWV reference ranges. In order to provide a reference base 
for the subsequent chapters in this thesis, a systematic review of the MR-PWV studies was 
collated for healthy participants in Table 1-3 and for various patient groups in Table 1-4, 
allowing comparison of previous published ranges.  
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1.10 Aim of thesis  
The purpose of this thesis is to examine the use of MR-PWV (i) to investigate whether 
PWV can be used as a surrogate MRI marker of macrovascular disease in a heterogeneous 
population with and without CVD, and (ii) whether these markers can provide greater risk 
prediction of CVD risk compared to established MRI parameters of cardiac function such 
as left ventricular mass. 
 
1.11 Specific Objectives of Thesis  
The specific objectives are:  
i. To implement and validate aortic PWV measurements as derived from 3.0T MRI 
velocity encoded images of the aorta in a healthy population. 
ii. To examine whether aortic PWV can be used as an imaging marker in high risk 
CVD patients with complications such as T2DM, hypertension and/or evidence of 
CVD complications such as CHD, stroke and PVD. 
iii. To extend the MR-PWV two slice assessment into a multi- site aortic assessment 
and to investigate its inter-scan repeatability in a cohort of young healthy volunteers 
(< 40 years of age). 
iv. To apply the multi-site aortic PWV technique to a cohort of healthy population and 
patients with PVD, to investigate if aortic stiffness varies at different sites along the 
aorta (aortic arch, distal and proximal aorta).  
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1.12 Outline of Thesis 
 
The structure of the thesis is as follows: 
Chapter 1  Thesis aims and design. 
Chapter 2  Introduction and literature review, covering a background to the 
haemodynamics of cardiovascular system, the prevalence of CVD and 
associated risk factors, and measurements of arterial stiffness using MRI.  
Chapter 3  MRI physics overview and description of the cardiac imaging sequences. 
Chapter 4 A description of the MRI hardware for image acquisition protocols and 
image analysis methods used throughout the thesis. 
Chapter 5  Two slice MR-PWV validation: method development, implementation and 
optimisation of the ‘standard’ MR-PWV protocol.  
Chapter 6 Clinical study I: Application of the MR-PWV ‘standard’ protocol to assess 
arterial stiffness in a heterogeneous complicated T2DM population with and 
without symptomatic CVD. 
Chapter 7 Multi-site MR-PWV validation: further development and application of a 
multi-slice PWV method, compared to conventional two slice approach, in a 
young healthy population. 
Chapter 8  Clinical study II: Application of multi-slice PWV method in a cohort of 
healthy volunteers and patients with PVD.  
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1.13 Overview of MRI Experiments and Patient Groups  
 
See Table 1-5 below for summary.   
Table 1-5 Summary of experimental chapters discussed in thesis.  
Chpt. 
Test hypothesis 
Cohort size 
(n) 
Cohort 
description 
Techniques tested 
CH 5 To test if PWV 
measurements can be 
derived from MRI and to 
compare with standard 
values from previously 
published studies and the 
effect of different methods 
3 cohorts of 
(n =10) 
OHV 
( > 40 years) 
HR-PWV 
LR- PWV 
Pre/post contrast 
Different transit time 
methods of estimating 
PWV 
Intra/inter PWV 
reproducibility 
CH 6 To assess if PWV can 
distinguish arterial stiffness 
in a heterogeneous 
complicated T2DM 
population with and 
without symptomatic CVD 
Total cohort 
n=88, 
 
G1: n = 23 
G2: n = 29 
G3: n = 19 
G4: n = 19 
 
G1: T2DM+ CVD 
G2: T2DM 
G3: CVD 
G4: Non CVD/    
T2DM controls 
LV analysis 
Aortic MR-PWV 
 
CH 7 To validate a multi-site 
PWV technique and 
compare with the 2-site 
conventional PWV 
technique 
Total cohort of n 
= 22 
YHV 
( < 40 years) 
LV analysis 
Standard MR-PWV 
Multi-site PWV 
Repeat scan of multi slice 
PWV 
CH 8 To apply the multi-site 
PWV technique to patient 
population with PVD 
Total cohort, 
n = 70 
 
YHV: n = 22 
OHV: n = 22 
PVD: n = 26 
YHV ( < 40 years) 
OHV ( > 40 years) 
and patients with 
PVD 
LV analysis 
Multi-site PWV 
Abbreviations: G: Groups, OHV: Older Healthy Volunteers, YHV: Young Healthy Volunteers, 
T2DM: Type-2 Diabetes Mellitus, CVD: Cardiovascular Disease, PVD: Peripheral Vascular 
Disease, PWV: Pulse Wave Velocity, HR: High Resolution, LR: Low Resolution, LV: Left 
Ventricle. 
 
41 
 
 CHAPTER 2
Physics of Cardiac MRI  
2.1 Introduction 
The aim of this chapter is to cover the basic physical principles underlying the most 
commonly used cardiovascular magnetic resonance (CMR) techniques. The chapter starts 
with a review of hardware, the basic principles of nuclear magnetic resonance signal 
generation and image formation and subsequently includes a technical review of CMR with 
a particular emphasis on the phase contrast imaging technique for PWV measurement in 
this thesis. 
2.1 Magnetic Resonance Imaging  
2.1.1 Hardware 
The hardware components of a MRI scanner include the magnet, gradient coils, 
radiofrequency (RF) coils (for transmitting and receiving), all supported by the system 
software which controls sequence parameters, timing and safety measures. All MR imaging 
in this study was performed on a 3.0 Tesla (T) MRI system (Magnetom Trio, Siemens, 
Erlangen, Germany).  
2.1.2 The Magnet 
The magnet is the core of the system and generates the static magnetic field for nuclear 
polarisation. The main magnetic field is homogeneous but contains inherent non-
uniformities which are minimised by system shimming. Magnet types include permanent 
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(~0.064 T - 0.3 T), resistive (up to 0.3 T) and superconducting (high field strengths up to 
12.0 T). The most common MRI systems in clinical practice utilise superconducting 
magnets with static fields of 1.5 T, however systems with greater field strengths of 3.0 T 
and 7.0 T are increasingly being used (Wood et al. 2012). The advantages of higher field 
imaging is a significant improvement in signal to noise ratio (SNR) due to increased 
polarisation of spins which can either improve spatial or temporal resolution or decrease 
imaging time.  
Cardiac imaging at higher field strengths can be problematic due to differences in tissue 
relaxation times, increased susceptibility artefacts and RF homogeneity issues. However, 
cine cardiac imaging at 3.0 T demonstrates high SNR, good blood-myocardium contrast to 
noise (CNR), high resolution and image quality (Nayak et al. 2004).  
2.1.3 The Gradient Coils  
An MR system has gradient coils in the x, y and z direction which enables it to image a slice 
in any plane of the body. To produce an image, gradient coils are used to spatially encode 
the position of protons by varying the magnetic field across the imaging volume. 
Application of different gradients and RF-excitation signals in a particular sequence and 
frequency, an image can be formed with faster and stronger gradients allowing for higher 
image resolution and faster image acquisition.  
2.1.4 Radiofrequency Coils  
RF coils are needed to transmit and receive radiofrequency waves used in image formation 
and receive only coils are generally specific to each body region. There are two types of RF 
coils; volume coils (e.g. head coils) and surface coils (e.g. spine coil). Most volume coils 
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are quadrature coils or circularly polarised and contain two loops of wire allowing more 
signal than single loop coils. However, they are closed coils so they are not practical for all 
applications.  
Surface coils have high SNR but have a limited sensitive area. To overcome this limitation, 
multiple surface coils can be combined and are known as phased array coils.  
The integration of the different MR components is illustrated in Figure 2-1. 
 
Figure 2-1 Basic components and hardware of an MR system: T/R: Transmit/ Receive. Adapted 
from (Mc Robbie et al, 2004). 
 
44 
 
2.2 Basic Principles of MRI 
2.2.1 Nuclear Magnetic Resonance Theory 
The basic unit of mater, the atom, hosts a dense central nucleus containing a mix of 
positively charged protons and electrically neutral neutrons. The protons and neutrons spin 
in motion at the same rate, but in opposite directions. If the number of neutrons and protons 
are equal, the net spin of the nucleus is zero. In the case of an unequal amount of protons 
and neutrons, the nucleus possesses a net spin. This intrinsic magnetic momentum is a key 
feature for MR. Commonly used nuclei includes hydrogen (H
1
), carbon (C
13
), sodium 
(Na
23
) and phosphorous (P
31
) (Balter 1987).  
 
Hydrogen is abundant in water and fat tissues in the body making it ideal for MRI. By 
virtue of this property of nuclear spin, the hydrogen nuclei in human tissue produce an 
electromagnetic field known as a magnetic dipole moment. When an external magnetic 
field is applied, the individual magnetic dipole moments align either high or low energy 
states, parallel or anti-parallel to the field, depending on the thermal energy of the spins. 
Under thermal equilibrium, a very small excess of low energy spins produces a net 
magnetic moment or equilibrium bulk magnetisation which is used to form the MR signal.    
When a nucleus interacts with an external magnetic field, the spins precess with a specific 
frequency, the Larmor frequency. The larger the field strength, the higher the precessional 
frequency, this relationship is described by the Equation 2-1.  
        2-1 
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Where ωo is the angular precessional frequency or Larmor frequency of spins, γ is the 
gyromagnetic ratio i.e. a constant that equals to 42.6 MHz/T for hydrogen nuclei, and Bo is 
the static magnetic field strength. 
 
When a radiofrequency (RF) pulse is applied, whose frequency matches the Larmor 
frequency, resonance occurs. Resonance results in the RF pulse transferring energy to the 
protons. During this process, some of the spins absorb a discrete amount of energy from the 
RF that causes a transition of spins from low to high energy state, resulting in the bulk 
magnetisation moving of alignment from equilibrium (B0). The angle between these vectors 
is known as the flip angle. When a flip angle of 90
0 
is applied, then all magnetisations move 
into the transverse plane, perpendicular to B0, where it rotates around at Larmor frequency. 
A flip angle less than 90
0 
allows only a portion of the magnetisation to be tipped over. The 
main purpose the RF pulse is to flip the longitudinal magnetisation  (Hashemi et al. 2012; 
Weishaupt et al. 2003).  
 
2.2.2 The Bloch Equation 
The Bloch equations can be used to model spin systems and these describe the time 
dependent behaviour of the magnetisation as it reverts back to the equilibrium state.  
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Figure 2-2 Spin magnetisation during thermal equilibrium: (a) after RF excitation, (b) and 
following dephasing of the transverse magnetisation Mxy (C). Adapted from  (Markl & Leupold 
2012). 
 
The different states of spin magnetisation are shown in Figure 2-2. Initially, the net 
magnetisation precesses along Bo at the Larmor frequency (Equation 2-2) 
      
  
            2-2 
Where M the net magnetisation vector in the x, y and z direction, B is the net magnetic field 
and γ is the gyromagnetic ratio.  
 
The application of an RF pulse at Larmor frequency causes the net magnetisation to be 
tipped towards the transverse plane at a particular flip angle, which is dependent upon the 
strength and duration of the RF pulse. Eventually, the net magnetisation will return back to 
its equilibrium value Mo due to spin-lattice interactions. (McRobbie 2007). 
 
47 
 
2.2.3 Nuclear Spin; T1 and T2 Relaxation 
The Bloch equations describe the recovery of the nuclear spin system as it returns to 
equilibrium (Mo). There are two types of relaxation processes; longitudinal and transverse 
relaxation. The first incorporates the return of net magnetisation into alignment with the 
main magnetic field and is known as longitudinal or T1 (spin-lattice) relaxation. This return 
to equilibrium is described by Equation 2-3 and takes the form of an exponential recovery 
characterised by time constant T1. This is an energetic process and involves the exchange of 
energy between the spin system and the tissue lattice via thermal mechanisms.  
 
            
 
 
    2-3 
where Mz is the longitudinal component of magnetisation, Mo is the magnetisation at 
equilibrium, and T1 is the relaxation time. 
 
The second relaxation process occurs due to the loss of phase coherence (without the loss 
of energy) between spins known as transversal or T2 (spin-spin) relaxation, following the 
RF pulse. The transversal magnetisation (Mxy) decays at a rate characterised by time 
constant T2 (Equation 2-4). 
 
          
 
 
   2-4 
Where Mxy is the transverse component of magnetisation , and T2 is the decay time. 
 
The decay rates of T1 and T2 are different since they can be considered as simultaneous but 
independent processes. The T2 decay occurs more rapidly due to dephasing of spins from 
both intrinsic and external factors. The time constant T2 depends purely on spin-spin 
interactions and only considers the loss of phase coherence due to spin interaction, which is 
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an irreversible process. However, magnetic field inhomogeneities and susceptibility effects 
result in additional dephasing known as T2*. The T2* decay results in a faster loss of signal 
than T2 and is described by Equation 2-5. 
  
   
 
 
  
 
 
 
    2-5 
Where γ is the gyromagnetic ratio, and ΔB is the variation in the magnetic field. 
 
The T1 and T2 relaxation times are dependent on the tissue properties. Additionally, T1 
values can vary corresponding to the strength of the main magnetic field, while T2 tend to 
show less dependency. Schematic exponential curves T1, T2 and T2* are shown in Figure 
2-3. 
 
Figure 2-3 T1, T2 and T2* relaxation: T1 curve: recovers to 63% of equilibrium (1−e
−1
), and T2, 
spin-spin decays back to 37% (e
−1
).  
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For MR imaging, the recovery or decay curve defines some of the intrinsic effects of tissue 
relaxation (T1, T2) needed for image contrast (Table 2-1). Other factors that also alter 
contrast include flow, perfusion and diffusion. In combination to these effects, MR 
generated extrinsic factors such as relaxation time (TR), time to echo (TE), time to 
inversion (TI) and flip angle can manipulate image contrast weighting and also provide 
spatial information for the image formation (Hashemi et al. 2012; McRobbie 2007).  
 
Table 2-1 Example of T1 and T2 relaxation times: T1 and T2 approximate values for 
liver, cartilage, heart and blood at 3.0 T (Stanisz et al. 2005). 
Tissue T1 [ms] T2 [ms] 
Liver 812 ± 64 43 ± 3 
Heart 1471 ± 31 47 ± 11 
Blood 1932 ± 85 275 ± 50 
 
2.2.4 Spatial encoding in MR  
In order to construct an image of the excited region of interest, spatial localisation of the 
signal needs to be determined. The received signal is defined by its frequency and phase as 
well as its intensity. Different gradients referred to such as the slice-select gradient, the 
frequency-encoding gradient and the phase encoding gradient are applied in three 
directions, Gz, Gx and Gy to obtain spatial information. This provides a spatial encoding 
scheme in which an accurate position of the MR signal can be defined as illustrated in 
Figure 2-4. 
Magnetic field gradients are produced and vary linearly over the area of interest or field of 
view (FOV). The gradients are bipolar with a positive component (added to Bo) and a 
negative (subtracted from Bo). 
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Figure 2-4 Application of a magnetic gradient: Illustration of gradient that varies linearly over 
the field of view. 
The gradient field induces a linear change to the spin’s precessional frequency. The 
negative gradient results in a lower magnetic field and causes the spins to precess at a 
frequency lower than the Lamour frequency and the positive gradient results in higher 
magnetic field and increased precession rates. For example, the application of the Gz causes 
the precessional frequencies to be a function of z, Equation 2-6. 
 
        2-6 
A standard pulse sequence is usually started by applying the slice selection gradient (Gz) in 
the presence of an RF pulse to localise spins. The Gz alters the precessional frequencies of 
spins located along the z-direction (along the magnetic field gradient) dependent upon their 
position in the direction of the gradient. The slice thickness can be controlled by altering 
the strength of the slice select gradient or by altering the bandwidth of the RF excitation 
pulse. 
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Following slice selection the next step is usually to apply a phase encoding gradient in the 
y-direction. This induces a phase change between proton spins by virtue of their position 
along the gradient. When the gradient is switched off the protons resume precession at the 
Larmor frequency but the pha se information is retained. In a simple pulse sequence the 
phase encoding gradient needs to be applied at different strengths (increments) in step-wise 
fashion for successive RF pulses in order to fully encode the data. This has an impact on the 
scan time such that the time taken for a simple sequence is equal to the TR multiplied by 
the number of phase encode steps. Finally, frequency encoding is applied along the x-
direction in order to readout the signal. This gradient allows spatial localisation due to 
protons precessing at a slightly higher frequency where the field is stronger, and slightly 
lower frequency at lower field.  It does not affect the time of the scan but the sampling time 
may have an effect on the number of slices that are possible. The echo is sampled during 
frequency encoding, where the individual frequencies comprising of the total signal are 
each identified via Fourier mathematics.  These steps are later shown in pulse sequence 
timing diagrams (Figure 2-6). 
 
2.2.5 K-Space 
Each repetition of the phase-encoding step generates a signal echo that can be digitised and 
stored in a data matrix known as k-space. Data points in k-space represent the spatial 
frequencies content of an MRI as illustrated in Figure 2-5.  
Every point in the raw data matrix contains information for the entire image. The outer 
rows of the raw data matrix contain high spatial frequencies and provide information 
regarding the details of the structure. The centre of the data space contains information on 
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the general contrast of the image. In order to convert the final image from k-space, Fourier 
transform is applied. 
 
 
Figure 2-5 K-Space in MRI acquisition: (A) K-space and(B) its associate image after Fourier 
transform. Adapted from (Moratal 2008). 
2.3 MR Pulse Sequences 
A pulse sequence is an ordered combination of RF and gradients applied to the object- 
usually shown as a timing diagram. As previously described, the different gradients are 
utilised in a particular arrangement to produce an image and these are categorised generally 
into either spin echo (SE) or gradient echo (GE) sequences. This thesis will deal with only 
GE sequences since these are by far the most common sequences for CMR.  
 
The time between the RF pulse and the centre of the echo is defined as the echo time (TE). 
This is the time at which the spins produce a maximum signal. The repetition time (TR) is 
the time between successive of RF excitation pulses. The pulse sequence is directly related 
to the filling of k-space by the application of magnetic field gradients to a premeditated 
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scheme, and when this is completed the image can be formed via Fourier transform. For 
example, if each TR interval contains one phase encoding step per slice, each of these 
signals fills one row of k-space corresponding to the Gy and is repeated Ny times to fill the 
entire k-space (McRobbie 2007).  
2.4 Gradient Echo Sequences 
The GE sequence starts off with a slice selection RF pulse (typically less than 90) in 
combination with a slice selection gradient (Gz) and uses opposite gradient polarities during 
frequency encoding (Gx) to form an echo. The spins are initially dephased and then re-
phrased by an opposite gradient. A peak signal is formed when the bipolar gradient 
(gradient with equal strength, but opposite polarity) in Gx (shaded regions in Figure 2-6) is 
implemented.  
 
Figure 2-6  Gradient echo pulse sequence: Basic gradient echo timing diagram, where RF is the 
radiofrequency, TE is echo time; TR is the time of repetition time and α is the flip angle.  
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GE sequences are generally bright blood techniques. They also have faster imaging speeds 
than SE sequences as their flip angle can be less than 90, and they do not require the use of 
a 180
o
 refocusing pulse. This helps to shorten the length of the time for T1 recovery, 
meaning that shorter repetition times can be used.  
 
The optimal flip angle for a particular tissue is known as the Ernst angle and is calculated 
from the TR and T1 values.  
 
         ( 
  
  
) 2-7 
Where the    is Ernst angle, TR and T1 is recovered.  
  
55 
 
2.4.1 Fast Gradient Echo Imaging  
Fast GE sequences use shorter TR times such that a steady state of the magnetisation  has 
built up during acquisition time (Markl & Leupold 2012). They generally exist in two main 
categories – spoiled GE and balanced ‘steady state’ free precession (bSSFP) GE.  For 
spoiled GE, the free induction decay signal is sampled during frequency encoding and any 
residual magnetisation is then destroyed (or ‘spoiled’) by the use of RF pulses or strong 
‘crusher’ gradients prior to the next TR.  For balanced GE (bSSFP) the gradients are 
arranged such that the net gradient area over one TR is zero along each axis, and this results 
in an efficient recycling of all available magnetisation s for MR signal generation (i.e. 
residual transverse magnetisation in the form of  a stimulated echo is subsequently included 
in the signal along with the FID) (Markl & Leupold 2012).  Steady state GE sequences such 
as True fast imaging with steady state precession (TrueFISP) are commonly used in CMR 
since they generate T2/T1 contrast that highlights the blood pool as hyperintense relative to 
the myocardial structures.  They offer good signal-to-noise but are prone to off-resonance 
artefacts if not correctly balanced. Fast GE techniques have many applications such as 
dynamic (CINE) cardiac imaging, MR angiography, assessment of tissue perfusion and 
viability.   
2.5 Additional Contrast  
In addition to the traditional T1, T2, T2* and proton density images, the use of contrast 
agents, mainly based on chelates of the  gadolinium ion (Gd
3+
) can be used in MRI 
(Strijkers et al. 2007). They predominantly used to shorten the T1 relaxation time and have 
been shown to provide a diagnostic role in coronary, myocardial perfusion and injury, 
peripheral and angiography (Saeed et al. 2000).  
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2.6 Cardiac MRI 
2.6.1 Challenges of Cardiac Imaging 
Cardiac MRI has become a routinely used modality in the investigation of patients with 
suspected cardiac disease and is considered to be the clinical gold standard for assessment 
of myocardial viability and cardiac function (Wieben et al. 2008). Compared to other 
anatomical regions, heart specific difficulties include cardiac and respiratory motion and 
flow phenomena which can lead to image artefacts. To overcome these difficulties, cardiac 
sequences need to be adjusted or acquired by specialist methods using synchronisation with 
the ECG trace, prospective or retrospective gating of data acquisition, and acquisition of 
data during respiratory gating or breath-holding, and utilisation of faster imaging 
sequences.  
 
i. Synchronisation with ECG 
The quality of cardiac MRI is highly dependent on consistent ECG triggering. Therefore 
using the electrical activity of the heart, MRI data can be acquired and synchronised to the 
corresponding mechanical event. To record this, MRI- compatible ECG leads are attached 
to the anterior chest of the participant to gate the examination. However these may be 
subjected to artefacts caused by the magnetohydrodynamic effect. Peripheral pulse gating 
(PPG) can also be used in this case via a pulse oximeter.   
 
ii. Prospective Triggering and Retrospective Gating  
The ECG can be used in different ways to facilitate image acquisition. One method is to use 
prospective gating where the presenting R-wave acts as a trigger to acquire information 
57 
 
during an R-R interval or cardiac cycle as shown in Figure 2-7. This can be adapted for 
either single segments for morphology imaging or a series of segments for multiphase 
imaging.  
The alternative method is to acquire the data continuously and to retrospectively match this 
to the ECG tracing. This is illustrated in Figure 2-7 and results in a cine study with a 
number of equally spaced temporal phases throughout the cardiac cycle. These multi-
cardiac phases are used for investigating the dynamic contraction and relaxation of the 
ventricles.  
 
 
Figure 2-7 Prospective triggering and retrospective gating of an ECG: The difference between 
prospective and retrospective is arrhythmia rejection (AR) period and retrospective is acquired 
throughout the R-R interval.  
ii. Faster Imaging 
Parallel imaging is used to accelerate the image acquisition in MRI data. It works by 
acquiring a reduced amount of k-space data with an array of receiver coils. The theoretical 
description of which is beyond the scope of this thesis. In a clinical setting, parallel imaging 
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results in faster image acquisition, which in turn can shorten breath-hold and reduce motion 
artefacts and is utilised in fast gradient echo imaging.   
 
2.7 Cardiac Imaging Sequences  
Image quality has significantly improved in cardiac imaging since the development of 
segmented data acquisition. Other developmental improvements have allowed high 
temporal and spatial resolution to be achieved in cine MRI sequences. Using SSFP 
sequences and parallel imaging, a full set of cine images can be obtained in 5 - 10 breath-
holds of approximately ten seconds.  Nevertheless, cardiac arrhythmias and patients that 
struggle with long breath-holds can still affect image quality. A brief summary of Fast Low 
Angle SHot (FLASH), TrueFISP and PC imaging will be provided as they are used in this 
thesis.   
2.7.1 (i) TrueFISP and FLASH 
As previously mentioned, both trueFISP and FLASH are commercial Siemens fast gradient 
echo sequences commonly used in cardiac MRI. Differences between solid structures such 
as the myocardium and flow can be achieved in both cine trueFISP and FLASH and mainly 
differ in the way they deal with residual magnetisation. TrueFISP steady state signal is 
determined by T2 to T1 ratio and provides excellent blood-myocardium contrast and ability 
to identify cardiac morphology.  
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FLASH generally relies on inflow enhancement to generate the blood-myocardial 
enhancement. Figure 2-8 shows an example of both a trueFISP and FLASH image of 25-
year old male with aortic regurgitation. In this case, the trueFISP (A) provides a clearer 
image of the regurgitation and the myocardial boundaries than the FLASH image (B).  
 
Figure 2-8 Comparison of TrueFisp and FLASH: Image of aortic regurgitation at located pointed 
by arrows where (A) is an axial trueFISP image (TR/TE 3.0/1.6) and (B) is an axial FLASH 
(8.0/4.0) (1.5 T Siemens Magnetom scanner, Pereles et al. 2001). 
 
Limitations of TrueFISP is its sensitivity to magnetic field non-uniformity and metal 
objects such as sternal wires can often result in inhomogeneity in the magnetic field 
resulting in image artefacts. In addition, phase cancelation artefacts are can be seen as dark 
etched outline at the interface between major structure interfaces such as fat and water. 
However, these artefacts are easily recognisable and generally not in the field of interest 
and with adequate shimming allow cine series to be of diagnostic quality for most patients. 
Saturation of signal in the blood pool can cause artefacts in FLASH images. Also due to its 
slightly longer acquisition time, cardiac gating and breathing motion artefacts can be more 
of an issue than the shorter trueFISP sequence (Pereles et al. 2001).  
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2.7.1 (ii) Phase Contrast MRI 
Phase contrast MRI (PC-MRI) is a technique based on the principle that moving spins 
acquire a phase shift in the presence of a magnetic field gradient. The phase shifts can be 
related to blood velocity by applying bipolar gradients. A bipolar gradient has two parts, 
each with equal area and opposite polarity.  It provides velocity profiles at any point of the 
cardiac cycle and is used clinically to measure flow in difficult regions and has superior 
spatial accuracy in comparison to other methods (Jung et al. 2004; Kilner et al. 2010). It 
has shown diagnostic application in cardiac function, heart valves, congenital heart 
diseases, major blood vessels, coronary arteries and myocardial wall velocity (Gatehouse et 
al. 2005). In this thesis, the traditional 2D PC-MRI sequence was used to estimate blood 
velocity in the aorta.  
 
Figure 2-9 Application of phase contrast: Sample planning and PC image for RV outflow track 
plane (a and b) and aortic flow quantification. Reference Selyavko et al, (2009).  
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Phase Contrast and Velocity Encoding 
The dynamic range of the measureable phase shift is limited to ± 180°. Therefore, the 
operator tunes the pulse sequence such that the peak velocity in the vessels corresponds to a 
phase shift of 180 or less. Velocity encoding (VENC) and has units of velocity- centimetres 
per second (cms
-1
) and the relationship between velocity and VENC is given below, where 
φ= [-π, π]. 
        
 
 
 2-8 
 
The VENC should be selected close to the peak velocity of the vessel, however if too low 
of VENC is selected, then aliasing will occur. If the VENC is too high, there will be an 
increase of noise and a loss of sensitivity of the output.  
 
Chapter Summary 
This chapter has provided an overview of hardware needed for cardiac applications.  The 
back-ground of cardiac sequences was reviewed such as trueFISP and FLASH and PC-
MRI. The set-up and methods will be further discussed in Chapter 4.
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 CHAPTER 3
Materials and Methods  
 
3.1 Introduction 
The principal technique used for the work carried out in this thesis was cardiovascular 
magnetic resonance imaging (CMR) as described in Chapter 3. All volunteers 
involved in these research studies were scanned at the Clinical Research Centre 
(Ninewells Hospital, Dundee) on a 3.0 T Magnetom Trio MRI scanner (Siemens, 
Erlangen, Germany). This section provides an overview of the general MRI scanning 
procedure and scan set-up for both clinical study participants (SUMMIT and 
TASCFORCE) and healthy participants.  
3.2 Study Ethics  
For research participants from both TASCFORCE and SUMMIT studies, the imaging 
protocols were reviewed and approved by the East of Scotland Research Ethics 
Committee. The study was conducted at Ninewells Hospital and Medical School, 
Dundee, UK in accordance with the Declaration of Helsinki. All volunteers provided 
written informed consent to participate in this study. 
Permission to scan healthy volunteers using 3.0 T Trio machine was covered by an 
existing agreement allowing scanning of consenting volunteers for validation and 
developmental work, equipment testing and generation of images for teaching 
purposes.  
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3.1 MRI Studies Protocols  
 
Participants in TASCFORCE and SUMMIT studies underwent an extensive MRI 
study protocol, designed to assess cardiac and aortic function and evaluate whole 
body atheroma burden. In total, the scan time for each participant ranged from 50-70 
minutes. The imaging protocols are discussed in the following sections and details of 
the specific scan protocols are outlined in Appendix A.  
3.1.1 Patient Eligibility  
The eligible study participants were safety screened before consenting to the MRI 
research study. MR specific exclusions include claustrophobia and the presence of 
metallic implants or devices such as surgical clips, pacemakers, artificial heart valves, 
metal joints or nerve stimulator in-situ.  
In the two clinical studies, a paramagnetic gadolinium based contrast agent was 
administered as per clinical protocol; therefore patients with impaired estimated 
glomerular filtration rate (eGFR) of < 30 ml/min /1.73 m
2
 were also excluded.  
3.1.2 Patient Positioning  
Patients were positioned head first and supine in the magnet bore, with surface coils 
used to cover the entire body namely the head matrix, neck matrix, spine matrix, two 
body matrix coils and a peripheral angiography coil as shown in Figure 3-1. Breath 
hold instructions were relayed via headphones and music played if desired. Coils 
covering the whole body were set-up on the participants from both clinical studies 
(SUMMIT and TASCFORCE).   
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Figure 3-1 Siemens 3.0 T Trio Scanner: CRC scanner set-up with typical whole body 
imaging coil set-up as used in both the TASCFORCE and SUMMIT studies. 
 
For the healthy volunteer validation study, only the body matrix coils were used as no 
contrast was administered to acquire whole body angiographic images.  Healthy 
volunteers underwent cardiac function and aortic flow quantification (as described in 
3.2, i and iii)  
3.2 Image Acquisition Protocol 
The protocol was split into three sections: 
1. Acquisition of the cine images acquired in 2 and 4 chamber orientations and a 
stack of cine images acquired in the short axis from base to apex to assess 
cardiac function.  
2. Dual injection of contrast and images acquired before and after these 
injections to image the whole body vasculature. 
3. Aortic flow quantification for the calculation of PWV.  
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3.2.1 (i) Localisers and 2-Chamber and 4-Chamber Views 
The cardiac protocol starts with reference images to accurately localise the heart. 
These low resolution slices (turbo FLASH) are acquired rapidly (~1 sec) in 3 planes 
(axial, coronal and sagittal planes) (Figure 3-2(a)) and are followed by localiser 
images acquired in the 2-chamber, 4-chamber and short axis (SA) views. The 
frequency scout, 4-chamber cine, 2-chamber cine and short axis cine are acquired 
using trueFISP. From these views, clinical qualitative assessment of myocardial 
function can be assessed. 
 
Figure 3-2 Different cardiac localiser orientations and the frequency scout: A. Localiser 
for cine 4-chamber, 2-chamber and SA views, shimming box (green box) over the selected 
volume, B. Frequency scout, range (-250 Hz to 250 Hz). Frequency scouts are utilised at 3.0 
T to determine the optimal resonance and minimise banding artefacts. 
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3.2.1 (ii) Left Ventricular Cardiac Function  
The SA images are used for quantitative analysis of the left ventricle. To evaluate 
systolic and diastolic LV functional parameters, ECG gated cine images were 
acquired through the LV using a multiple short-axis cine sequences from the mitral 
valve to the apex. Slices are acquired sequentially at 1 cm intervals through the entire 
left ventricle (slice thickness of 6 mm and an inter-slice gap of 4 mm). Further details 
of this method used are described by Gandy et al. 2008.   
 
Table 3-1 Sequence parameters for LV assessment: Short-axis stacks of CINE TrueFISP 
images of the LV acquired from the base of the mitral valve to the apex.  
Parameter 3.0T (Siemens) 
Repetition Time (ms) 86.6 
Echo Time (ms) 1.47 
Field of View (mm) 320 x 420 
Matrix 256 x 256 
GRAPPA factor 2 
Flip angle 50 - 60° 
Slice thickness (mm) 6 
Inter-slice gap (mm) 4 
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3.2.2 Whole Body Magnetic Resonance Angiography Protocol 
For localisation, four low resolution images were acquired from head to foot in the 
coronal orientation using gradient echo fast FLASH sequence. Whole body magnetic 
resonance angiography (WB-MRA) images involved the acquisition of 4 overlapping 
3D data sets as shown in Figure 3-3.  
Four anatomically distinct stations were divided into head and thorax (station 1), 
thorax and abdomen (station 2), abdomen and upper legs (stations 3) and lower legs 
(station 4).  
Table 3-2 Sequence parameters for WBA imaging: The parameters for pre and post 
contrast 3D FLASH sequence used at 1 station. WBA involves the acquisition of 4 
overlapping 3D data sets.  
Parameter 3.0T (Siemens) 
Repetition Time (ms) 2.68 
Echo Time (ms) 1.10 
Field of View (mm) 500 x 360 
Flip angle  19° 
Number of slice  96 
Voxel size (mm
2
) 1.0 x 0.8 x 1.1 
Slice thickness (mm) 1.1 
 
Anatomical paired images were acquired pre- and post-contrast. Gadoteric acid 
contrast agent (Dotarem, Guerbet, Villepinte, France) was administered by 
intravenous injection into antecubital fossa using a Spectris Solaris power injector 
(MedRad, Pittsburgh, USA) at a rate of 1.5 ml/sec, followed by a 20 ml bolus of 
saline. Further details of this methods used in this centre  (Waugh et al. 2009) and 
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results for the WBA (not included in this thesis) are presented in Weir-McCall et al 
(under review). 
 
Figure 3-3 Whole body magnetic resonance angiogram: WBA is made up of four imaging 
stations 1 to 4, head and neck, aorta and abdominal, illiofemoral and the run off peripheral 
vessels. Adapted from Weir-McCall (under review).    
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3.2.3 (i) Phase Contrast Imaging of Aortic Flow 
To generate flow and mean velocity waves, PC-MRI sequences were acquired at the 
level of the bifurcation of the pulmonary trunk, perpendicular to both ascending and 
descending aorta and the second slice was placed axial through the descending aorta 
immediately proximal to the renal arteries. The PC-MRI data was acquired 
continuously using a retrospectively, ECG-gated breath-hold gradient echo sequence 
with a velocity encoding gradient in the through plane direction, which provides 
phase related pairs of modulus and velocity encoded image as shown in Figure 3-4. 
Retrospective gating was employed in order to avoid an end diastolic gap in data 
acquisition. The image acquisition details are described in Table 3-3. 
Table 3-3 Sequence parameters for PC-MRI imaging: PC-MRI gradient echo sequences 
were acquired at the aortic arch. 
Parameter 3.0T (Siemens) 
Repetition Time (ms) 14 
Echo Time (ms) 4.83 
Field of View (mm) 350 
Flip angle  20° 
Slice thickness (mm) 8 
Resolution 256 x 256 
Number of phases 128 
VENC (cm.sec
-1
) 150  
Average Scan Time 4 - 6 mins 
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Figure 3-4 Through-plane cine PC-MRI mapping: (i) magnitude and (ii) phase at the 
aortic arch, and (iii) magnitude and (iv) phase above the renal bifurcation. Abbreviations: 
AA: ascending aorta, DA: descending aorta. 
 
3.2.3   (ii) Aortic Distance Measurement  
To determine the distance between the two aortic slices, a 2D GE FLASH was 
acquired of the aorta in a ‘candy stick’ double-oblique orientation (Figure 3-5 (A)). 
The scan parameters are detailed in the Table 3-4.  
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Table 3-4 Pulse sequence parameters for 2D FLASH: 2D FLASH of the aorta is used to 
measure the distance between imaging sites.  
Parameter 3.0T (Siemens) 
Repetition Time (ms) 40 
Echo Time (ms) 1.2 
Field of View (mm) 350 
Flip angle  15° 
Slice thickness (mm) 8 
Resolution 256 x 256 
No of phases  23 
Average scan time (s) 9 
 
The data in this thesis used the FLASH ‘candy cane’ image for distance 
measurements; however the aortic path can also be visualised by a multi-planar 
reconstruction (MPR) from the angiographic images as shown in Figure 3-5 (B). 
 
 
Figure 3-5 Aortic distance measurement: A. FLASH ‘candy-cane’ view of the aorta B. 
MPR reconstruction of the aorta.  
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3.3 Post Processing of Cardiac Images  
3.3.1 Left Ventricle Assessment  
CMR is considered ‘gold standard for measuring cardiac volumetric and mass; 
however there are different methods for cavity delineation to deal with the inclusion 
and exclusion of trabeculae and papillary muscles (Papavassiliu et al. 2005). For this 
study, the LV segmentation followed an in-house optimised protocol, previously 
described by Gandy et al. (2008). Semi-automated contours were placed on the 
endocardial and epicardial myocardial borders at end-diastolic and end-systolic 
phases from the basal to the apical slice. These were then manually adjusted to ensure 
that the contours precisely matched the anatomic detail. Papillary muscles and 
trabeculae were included in the LV mass when they were indistinguishable from the 
endocardial border, but otherwise assigned to the LV blood pool volume. All images 
were acquired during 10-15 second breath-hold and were post-processed by two 
experienced segmenters using dedicated Argus software (VB15, Siemens), Figure 3-6.  
 
Figure 3-6 Post processing of short axis LV images: A. Descriptive of short axis (SA) 
image. Left ventricle volume planned from the 4-chamber view, B. to get the SA image, C. 
The endocardial and epicardial boundaries are manually segmented using Argus at end 
diastolic (ED) and end systolic (ES) phase to derive quantitative measures of LV function 
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Parameters such as EF, EDV, ESV, SV, CO or CI and left ventricular mass (LVM) 
were automatically calculated by the software using Simpson’s rule. These parameters 
were normalised to body surface area. Cardiac output and index are derived from SV 
and heart rate and although they are an output of analysis they are rarely used. This is 
due to the intrinsic fluctuations in heart rate that frequently result in a high variability 
in the measure. Therefore, these measures were excluded from the statistical analyses 
in this work.   
3.3.2 (i) Aortic Flow Analysis  
 
Flow analysis was derived using the ‘flow analysis’ module on the freely available 
open source software package  Segment version 1.9 R10 (Heiberg et al. 2010a). 
Contours were placed on the ascending and descending aorta for all 128 phases 
throughout the cardiac cycle using a semi-automated process as shown in Figure 3-7. 
 
Figure 3-7 Phase contrast MRI: A. Magnitude and B. PC-MRI images acquired 
over a R-R cycle over 128 phases 
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From these contours, the software calculated volume flow curves, positive and 
negative flows, mean velocity curves and vessel area curves. It can also provide a 3D 
profile of flow, which allows a visual examination of skewness of flow profiles 
(Heiberg et al. 2010b) as shown in Figure 3-8. 
 
Figure 3-8 Flow analysis software: Segment flow analysis software with ascending 
(red) and descending (blue) flow curves. (B) 3D flow map the ascending flow ROI 
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(ii)  Aortic Distance Measurement  
The aortic path length between the imaging sites was measured using the software 
package Argus (Siemens Medical Systems, Germany), visualising the course of the 
thoracic aorta (as shown in Figure 3-5). This was repeated 3 times and a mean 
distance was used to calculate PWV as mentioned previously in Equation 1-3 
(Brandts et al. 2012).    
3.3.3 Statistical Analysis 
Statistical assessments in this thesis were performed using Statistical Package for the 
Social Science (SPSS), Version 21.0 for Windows (IBM Corporation, Armonk, New 
York) and significance was assumed at P < 0.05. Means were shown with standard 
deviation (SD). Bland-Altman analysis was used to assess agreement and performed 
with 95% confidence intervals by Graphpad Version 6.0 (Windows, GraphPad 
Software, La Jolla California USA). Further specifications of specific statistical tests 
used are outlined in each experimental chapter.  
 
3.4 Summary 
This chapter summarises general methods and tests used throughout Chapter 4 to 7. In 
particular, a general set-up and protocol has been described for cardiac imaging, 
whole body angiography and assessment of aortic flow as well as relevant imaging 
processing tools. As this thesis investigates the development and validation of PWV, 
there is further commentary on the utilised PWV protocol in Chapter 4.  
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 CHAPTER 4
Validation of MRI Derived Pulse Wave Velocity  
 
4.1 Introduction  
Aortic stiffness has been shown to be an important diagnostic and prognostic factor of 
CVD, as well as an estimate of overall cardiovascular health (Ben-Shlomo et al. 
2014). Surrogate markers such as aortic PWV and distensibility have been validated 
as indicators of aortic stiffness and aortic elasticity index. To quantify aortic PWV 
and distensibility from MRI, an imaging protocol and diverse segmentation tasks need 
to be applied. 
 
Firstly, to design a study protocol several imaging parameters, sequence selection and 
setup orientations need to be determined.  A review of recent studies protocols 
provides guidance in this process, although further in-house optimisation is needed to 
correct for different vendors (Philips, Siemens or General Electrics), field strength 
(1.5 T versus 3.0 T) or variation in commercially available sequences. Other in-house 
decisions for PC-MRI acquisition include; what range of velocity encoding (VENC) 
needs to be applied, do the images need to be of high resolution, length of scan time, 
should the acquisition be before or after administration of a contrast agent and how 
many time-points are needed along the R-R cycle. In MR imaging, there are well 
known trade-off between resolution, SNR and acquisition time. A compromise 
between the different factors is made in order to have an output with sufficient 
77 
 
information for the image analysis process e.g. high temporal resolution may be more 
important than spatial resolution.  
Following image acquisition, three outputs are needed to derive PWV such as 
segmentation of different aortic regions on the velocity encoding image, the analysis 
of the pulse waveform and extraction of the aortic centre line between the different 
slices. For each of these steps, different software, methodologies and analysis need to 
be performed. The overall purpose of this chapter was to evaluate the performance 
and repeatability of the use of PC-MRI in order to calculate PWV through a pilot 
investigation. Preliminary investigation included healthy participants with no previous 
evidence of CVD. Different methods of calculating PWV by transit-time (TT) were 
examined to evaluate which method was the most robust for studies within this thesis. 
The anticipated outcome of this chapter was an optimised PWV protocol that could be 
implemented as part of a research study protocol (Chapter 5, SUMMIT study). 
 
  
78 
 
4.2 Study Aims  
The aims of this chapter were: 
i. To provide in-house validation for estimating aortic PWV via from a small 
cohort of healthy participants (n = 10) without prior history of CVD 
ii. To optimise sequence parameters such as in-plane resolution, velocity 
encoding settings 
iii. To determine if PC-MRI images are affected by MR-contrast in order to 
determine if the sequence should be placed either pre or post contrast in a 
scanning protocol 
iv. Comparison of different transit time segmentation techniques that can estimate 
aortic PWV (transit time, foot to foot method and upstroke) and to verify their 
intra- and inter-observer reproducibility.  
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4.3 Methods 
4.3.1 Demographics and Baseline Characteristics 
For this study, three groups (n = 10, in total n = 30) of an older (above 40 years) 
healthy population were recruited. None of the volunteers had a previous history of 
adverse cardiovascular events or hypertension. All MR examinations were performed 
with setup as described in Chapter 3.  
 
A summary of the groups demographics are displayed in Table 4-1. All participants 
underwent a standard cardiac protocol, after which each group of n = 10 underwent 
one of the three experimental protocols of PC-MRI.   
 
Group 1:  High resolution PC-MRI, at both the aortic arch and the descending 
aorta, proximal to the renal bifurcation. Inter and intra-operator image 
analysis was performed on this group, comparing this in each of the 
different methods of PWV calculation (time to upstroke, time to foot 
and time to point). 
Group 2: Two PC-MRI acquisitions at the aorta arch, a high resolution (256 X 
256 matrix) with a scan time of approximately 6 minutes), and the 
second of lower resolution acquisition (192 x 192 matrix, scan time 
approximately 4 minutes). 
Group 3:  A high resolution acquisition of the aortic arch was performed pre-
contrast injection early in the scan, and post-contrast administration 
(after a dual bolus injection). Images were compared to assess the 
effects of contrast media on the PWV calculation.  
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Table 4-1 Demographics for groups: Older healthy volunteers (OHV) scanned with 
different PC-MRI parameters (group 1-3) to evaluate if there was an impact on PWV 
estimation 
Descriptive Group 1 Group 2 Group 3 
Age (years) 60 ± 9 52 ± 8 51  ± 7 
Gender 5M:5F 3M:7F 3M:7F 
Sample size (n) 10 10 10 
 
4.3.2 Image Acquisition and Analysis 
To extract flow and mean velocity waves, PC-MRI sequences were acquired using 
protocol as described in Methods and Materials (3.2.3) and distance between slices 
was measured from a ‘candy stick’ 2D FLASH aortic image as shown in Figure 3-5.  
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4.3.3 Comparison of PWV Transit-time Techniques  
Several mathematical algorithms have been proposed for calculating transit-time 
calculation (Butlin et al. 2008; Dogui et al. 2011). The three most commonly used 
methods are; time to upstroke, time to foot and time to point. The intra and inter-
observer reproducibility of each of these techniques was tested in estimating PWV.  
 The time to upslope (TTU) method, calculates the arrival time of the pulse 
wave from the intersection of the systolic up-slope of the velocity curve and 
the baseline velocity. The systolic upslope is defined as the line connecting the 
points at the 20% and 80% of the maximum velocity in the waveforms.  
 The second technique used the time to foot (TTF) method of the wave and 
provides the time changes between the foot of the velocity curves of the 
ascending and descending aorta. This type of estimation is commonly used in 
tonometric CF-PWV studies (Laurent, Cockcroft, Van Bortel, et al. 2006). 
The foot of the curve was defined as the intersection between the horizontal 
line passing through the baseline and the linear regression is modelled 
between the initial 10% and 30% of the systolic upslope. 
 The time to point (TTP) method uses a single point at the half maximum point 
of the wave.  
 
An example of these three transit-time methods is illustrated in Figure 4-1. Analysis 
and calculation of the PWV was measured twice by a single observer (DC) and once 
by a second experienced observer (JWC) to determine intra and inter-operator 
repeatability. 
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Figure 4-1 PWV Transit-time calculation: (Top) Aortic sites used for convention 2-slice 
PWV method where AA: ascending aorta, DA: descending aorta and LDA: lower descending 
aorta. (Bottom) Graph of flow waveform from each of the aortic sites after analysis for each 
of the transit time methods: TTU, TTF and TTP. 
 
For each of these methods, the time interval at each site was determined and plotted 
against its corresponding distance along the aorta (AA, DA OR LDA). This 
relationship was modelled using a linear regression, and the inverse of this slope used 
to elicit the mean aortic PWV value.  
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4.3.4 Statistical Analysis  
The different measurements (TTU, TTF, and TTP) were compared to each using a 
paired and unpaired t-test, with P < 0.05 considered statistically significant. 
Regression analyses were used to test the relationship between techniques. Percentage 
co-variance (CoV) was calculated as SD over mean PWV of the group. Inter-observer 
reproducibility was tested using Bland-Altman (difference vs. average method), with 
upper and lower confidence intervals of 95% (Bland & Altman 1999).   
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4.4 Results 
4.4.1 Transit-time Estimation of PWV 
Using a sample (n = 10) healthy volunteers, different transit-time estimators were 
tested to see which method provided a more repeatable result. The average co-
variance was lowest in the TTU (9.4%) and higher in both TTF and TTP method 
(22.4%, 25.6%). For the TTU and TTF method, good agreement was found between 
observers (r
2 
= 0.90, 0.94), however a lower correlation between observers was found 
with the TTP method (r
2 
= 0.64), (Table 4-2).   
Table 4-2 Comparison of different transit-time estimators. 
 
PWV 
measurement 
(ms
-1
) 
Repeated 
PWV 
measurement 
(ms
-1
) 
Repeated by 
different 
operator 
(ms
-1
) 
Regression 
Analysis 
between 
observers 
(r
2
) 
Av. Cov % 
TT-Upslope (TTU) 5.67 ± 0.9 6.16 ± 0.5 6.10  ± 0.5 0.90 9.4% 
TT-Foot (TTF) 6.32 ± 2.1 6.69 ± 1.6 6.63  ± 1.5 0.94 22.4% 
TT- Point (TTP) 6.89 ± 2.8 6.70 ± 2.6 7.35 ± 1.8 0.64 25.6% 
M e a n  P W V  fo r  B o th  O b s e rv e rs  (m /s )
P
W
V
 (
m
/s
)
O
B
1
 T
T
U
O
B
2
 T
T
U
O
B
1
 T
T
F
O
B
2
 T
T
F
O
B
1
 T
T
P
O
B
2
 T
T
P
0
5
1 0
1 5 * *
 
Figure 4-2 Transit-time PWV methods: Dot and scatter plot of the mean PWV for each of 
the transit-time techniques (TTU: Transit Time Upslope, TTF: Transit Time Foot: TTP: 
Transit Time Point) for two observers (OB1 and OB2). A difference in mean PWV was found 
with TTP method in comparison of TTU and TTF (paired t-test, *P <0.05).   
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Means between the techniques were tested using paired t-test. TTU and TTF did not 
show significant difference between techniques (P = 0.23), however TTP showed 
significant with both TTU (P = 0.04) and TTF (P = 0.02).  
 
Bland-Altman plots were performed by calculating the difference (A  - B) vs. average 
with confidence intervals of 95% in Figure 4-3.  
 
 
Figure 4-3 Bland-Altman (left) and regression correlation (right) for Transit-
time methods: Where A. upslope (TTU) - A, B; TT-foot (TTF)- C, D and TT-Point 
(TTP)-E, F.  
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4.4.2 Optimisation of Imaging Protocol 
 
(i) Effect of In-plane Resolution  
Different in-plane resolution was applied. The results of both high (256 x 256) and 
low (192 x 192) in plane spatial resolution PC-MRI images are displayed in Table 
4-3. 
Table 4-3 Results from using different in-plane resolutions. 
 
In-Plane Resolution 
PWV measurement 
(ms
-1
) 
Repeated PWV 
measurement (ms-1) 
Average 
Acquisition Time 
(min) 
PWV High Resolution 5.79 ± 0.8 5.88 ± 0.9 06:12 ± 0:45 
PWV Low Resolution 7.89 ± 2.5 6.85 ± 2.1 04:25 ± 0:30 
 
From these results, PWV values with higher in-plane resolution were seen to be more 
reproducible and showed less variance when repeated.  
(ii) Effect of MR Contrast on PWV  
A single slice high resolution PC-MRI was analysed pre and post-contrast. No 
significant difference was found between the mean PWV pre and post contrast (paired 
t-test, P > 0.05) (Table 4-4).  
Table 4-4 Results of effect acquiring PWV pre and post-contrast 
Acquisition time PWV (ms
-1
) 
Average 
Acquisition 
Time (mins) 
% CoV 
Regression 
Analysis (r
2
) 
Pre-contrast 6.14 ± 1.4 06:12 ± 0:45 18.2% 0.84 
Post-contrast 5.62 ± 1.3 06:12 ± 0:45 19.2% 0.82 
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An example of a flow waveform for a partipiant pre and post the bolus injection of 
contrast is displayed in  
Figure 4-4.  
 
 
 
Figure 4-4 Flow waveform pre and post contrast: A flow analysis of pre (red) and post 
(blue) contrast at the ascending aorta for a healthy volunteer (n = 1). The administration of 
MR-contrast had no significant effect on determining PWV (paired t-test, P > 0.05). 
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Table 4-5 Summary of key results: Validation of MR derived PWV 
Investigation Results 
I. Transit time methods of estimating PWV 
 
Which transit time method had the lowest 
variance between a healthy cohort? 
 The average covariance was lowest in the TTU 
(9.4%) and higher in both TTF and TTP method 
(22.4%, 25.6%). However statistical significance 
was only seen in both TTU, TTF versus TTP          
(P < 0.05). 
 
Which transit time method showed the 
best inter and intra reproducibility? 
 
 For the TT-upslope and TT-Foot method, good 
agreement was found between observers (r
2 
= 
0.90, 0.94), however a lower correlation 
between observers was found with the TT- Point 
method (r
2 
= 0.64) 
Recommendation  The TT-upslope showed the best co-variance 
and repeatability between observers 
II. Optimisation of imaging protocol 
Does high and low resolution PC-MRI 
imaging effect PWV result? 
 Reducing resolution shortens the scan time by 2 
minutes. 
 Contour boundaries were more defined in higher 
resolution images, making segmentation easier 
with resultant improved reproducibility.  
Recommendation:  Use high resolution velocity encoding imaging 
for higher reproducibility. 
Does the administration of contrast 
provide any additional value to PC-MRI 
imaging? 
 No significant change was seen pre or post 
contrast on single slice acquisition 
Recommendation 
 PC-MRI images for MR-PWV can be placed 
either before or after contrast without any 
significant effect with PWV 
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4.5 Discussion  
 
Several studies have previously evaluated MR-based measurements of PWV with 
intravascular pressure measurements (Grotenhuis et al. 2009) and applanation 
tonometry as a reference standard (Rogers et al. 2001; Suever et al. 2011). This 
chapter provides preliminary results of our in-house initial testing of PC-MRI MR-
PWV methods such as technique reproducibility and the effect of scanner variables. 
The aim of this chapter was to provide experimental results in order to optimise the 
protocol for a clinical study (Chapter 5). A summary of the key findings are shown in 
table below. 
 
Transit Time Analysis Methods for Estimating PWV  
The temporal shift between the two waveforms at different sites through the 
vasculature gives an indication of the stiffness the vessel. The shorter the temporal 
shift, the greater the vessel stiffness resulting in higher PWV value. The computation 
of transit time for PWV depends on various waveform characteristics and can be 
computed by the TTU, TTF or the distance between the mid-point of the curve (TTP). 
In this validation work, all these methods were assessed and tested for repeatability 
and covariance distribution of the small sample cohort of ten healthy volunteers.  Our 
results in this study showed that the average co-variance was lowest in the TTU 
(9.4%) and higher in both TTF and TTP method (22.4%, 25.6%). When 
reproducibility was tested between two observers, the TTU and TTF method showed 
good agreement between observers (r
2 
= 0.90, 0.94), however a lower correlation 
between observers was found with the TTP method (r
2 
= 0.64). From this preliminary 
analysis, we can see that the upstroke method shows more robustness and better 
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reproducibility than the other methods so it will be used for any further PWV analysis 
in this thesis.  
 
Image Acquisition: In-Plane Resolution  
After a review of current literature (1.8.7), it is evident that there is no standard 
approach. PWV studies have used both through-plane and in-plane aortic orientations, 
and different PC-MRI parameters, such as in-plane resolution. To experimentally test 
the effect of changing in-plane resolution, a small cohort of ten healthy participants 
received both a high and low spatial resolution PC-MRI at the aortic arch and 
analysed to determine the PWV. The purpose behind trying to reduce the in-plane 
resolution was an attempt to reduce scan protocol time for the clinical study with the 
heterogeneous diabetic and cardiovascular population. The results from this study 
showed that reducing the high resolution image matrix from (256 x 256) to a lower 
resolution (192 x 192), showed a reduction of 2 minutes in scan acquisition time. 
However, the lower resolution images shows higher variance than the high resolution 
acquisition and proved to have poorer intra-operator reproducibility too. This may be 
due to a poorer SNR of the lower resolution images, making image segmentation and 
boundary definition more difficult and hence affecting the PWV measurement. As the 
aim of the clinical study was to investigate if we could see early arterial stiffness in 
T2DM patients, the high resolution acquisition was selected for final protocol.  
 
Image Acquisition: Pre and Post Contrast  
The patients in the clinical study received contrast as part of a whole body angiogram 
acquisition. It was therefore questioned if the administration of contrast would affect 
the velocity encoding imaging and thus effect the placement of the acquisition in the 
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protocol i.e. pre and post-bolus of contrast. Some studies have suggested in the case 
of 4D flow acquisition, contrast can improve the SNR slightly and thus improve 
image quality (Bock et al. 2010). However, no effect was seen in our study, so it was 
therefore decided that the PWV acquisition could be performed towards the end of the 
scan.  
 
In conclusion, this study has highlighted that adapting a high resolution in plane 
acquisition and using TT-upstroke estimation method would provide an optimal PWV 
acquisition protocol. We have also demonstrated that the effect of image acquisition 
pre or post bolus injection of contrast will not affect our results and it has been 
therefore decided that PWV will be placed at the end of the scanning protocol of the 
clinical study.  These experiments have provided preliminary data to assist in the 
protocol design and acquisition.  
 
Study Limitations  
These experiments recruited participants in an opportunist nature, with small groups 
of 10 patients sequentially selected to test each of the experiments. The aim of this 
study was to gather preliminary data to test and optimise the PWV acquisition to be 
later implemented into the clinical study protocol. For the TT methods experiment, a 
group of patients received two-slice PWV ‘standard’ set-up as described in papers 
(van der Meer et al. 2007; Ibrahim et al. 2010). However the results obtained in this 
experiment are not comparable to the in-plane resolution or pre and post contrast 
study as they only had a single slice PWV acquisition due to scan time restrictions 
and were demonstrated on different cohorts of volunteers.   
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4.6 Summary  
This preliminary work aimed to test the effect of various MR acquisition setups such 
as image resolution and the effect of contrast on the calculation of PWV. Different 
methodologies for estimation of transit-times were also examined for both intra and 
inter-observer variation. The final results of this validation have been used for 
optimising the PWV of the clinical study protocol as shown in the following Chapter 
5.  
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 CHAPTER 5
Aortic Stiffening in Type-2 Diabetes and Cardiovascular 
Disease 
 
5.1 Introduction 
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease resulting in an 
inability to control glucose homeostasis due to insulin resistance. In many countries, 
T2DM is reaching epidemic proportions due to an ageing population, with an 
increasing prevalence of obesity and sedentary lifestyles. The disease is associated 
with high morbidity and mortality due to cardiovascular macro and micro-vascular 
disorders such as stroke, CHD and PVD, as well as nephropathy and retinopathy. 
Such complications can impose a significant burden on the quality of life of diabetic 
patients. As a consequence, there is a need for methods to detect cardiovascular 
degeneration in diabetic patients at an early stage of disease development before these 
conditions emerge as an adverse event. Increased aortic stiffness, as measured by 
PWV, may provide an important marker of disease development, linking T2DM with 
CVD. Indeed, a study by Van der Meer et al (2007) utilised MR-PWV in the 
assessment of aortic and cardiac function in uncomplicated T2DM patients. It was 
uncovered that patients with T2DM had increased PWV, lower aortic distensibility 
and compromised LV diastolic function, compared to age matched controls, showing 
coherency to the other studies on metabolic syndrome (Cruickshank 2002; Roes et al. 
2008; Lee et al. 2007b).  
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As previously reviewed in Chapter 1, MR-PWV can be derived from flow analysis at 
different aortic locations using PC-MRI and has shown good reproducibility with the 
gold standard invasive pressure measurements (Westenberg et al., 2011, Grotenhuis et 
al., 2009). The aim of this study was to evaluate MR-PWV in a complicated diabetic 
population with and without symptomatic CVD, and to interrogate if it bares an 
impact on LV function.  
 
5.2 Study Aims  
The aims of the research presented in this chapter were:  
i. To implement a validated MR-PWV technique on four cohorts of patients 
covering early uncomplicated T2DM, through to later stages (0 - 24 years 
duration) with clinical evidence of CVD (CHD, stroke and/or PVD);  
ii. To investigate if there are any correlations between LV function and aortic 
PWV 
iii. To determine if aortic PWV can discern any difference on aortic stiffness 
between T2DM patients and patients without T2DM.  
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5.3 Methods 
 
5.3.1 Study Participants 
The participants in this study were recruited as part of the SUMMIT project (as 
described in Preface), to which 156 participants underwent an MRI as part of imaging 
work-package 4. Study participants were recruited from multiple sources across local 
and national networks such as the Health Informatics Centre (HIC), Scottish Primary 
Care Research Network (SPCRN), Scottish Diabetes Research Network (SDRN), 
local advertising and from the Secondary Care Diabetes Clinics (SCI-DC). All 
participants were over 40 years of age and after initial evaluation, they were assigned 
into one of the following cohorts in Table 5-1. These grouping will be referred to for 
the rest of the chapter.  
 
Table 5-1 SUMMIT Groups: Classification of each of the four groups with and without 
T2DM and with and without CVD. *The sample sizes of each of the groups was based on 
intended MRI recruitment for the study. 
No. Description of cohort Sample size 
Group 1 Participants with T2DM with CVD n = 50* 
Group 2 Participants with T2DM without CVD n = 50* 
Group 3 Participants without T2DM and with CVD n = 25* 
Group 4 Participants without T2DM and without CVD n = 25* 
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5.3.2 Eligibility Criteria 
(i) Screening Interview  
Each participant underwent a screening interview with research nurses (Scottish 
Diabetes Research Network) in which medical history, anthropometric measurements, 
venous blood, and urine collection was taken as outlined by SUMMIT case report 
form (CRF), which is included in Appendix A. For medical history; diabetes history 
(age at diagnosis, presentation, treatment and complications), document of other co-
morbidities including cardiovascular status, significant past medical history, 
concomitant medication and smoking status was recorded. Participants’ height, 
weight, hip and waist circumference were measured, their body mass index (kg.m
-2
) 
and hip to waist ratio were calculated from these values. Resting blood pressure was 
measured three times with participants in the supine position with Omron M6 
(OMRON Healthcare, Europe, Hoofddorp, The Netherlands).  
 
Informed consent was obtained from all subjects with ethical approval from the local 
ethics commission, East of Scotland Research Ethics Service. SUMMIT receives 
support from the Innovative Medicines Initiative (IMI) Joint, undertaking under the 
grant agreement n° [115006], resources of which are composed of financial 
contribution from the European Union's Seventh Framework Programme (FP7/2007-
2013) and EFPIA companies' in kind contribution. 
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(ii) MRI Participants 
Additional MR specific exclusions were applied as outlined in Chapter 3.1.1. A total 
of 156 eligible volunteers participated in the MRI section of the SUMMIT study; 
however 6 opted out before the scan.  
 
A final total of 146 participants underwent cardiovascular MRI protocol with all 
participants having WBA, n = 144, having LV assessment and 90 participants 
continuing to have an aortic assessment for PWV measurement. A detailed 
breakdown of target recruitment and final MR participants is outlined in Figure 5-1. 
As this study is focused on PWV, the rest of the results will only include participants 
that had both PWV and LV assessment (n = 90).  
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Figure 5-1 SUMMIT recruitment flow diagram for MRI cardiac assessment and aortic flow quantification: Final recruitment for LV assessment was n 
= 144 and for aortic flow quantification was n = 88. *The first 23 scans were under an older protocol and excluded for this study. 
#
 Extreme outliers at 3 SD. 
over the mean  
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(iii) Type 2-Diabetes Participants 
The inclusion criteria for G1 and G2 included diagnosis of T2DM after the age of 35 and 
not on insulin for the first 12 months of disease. The non-diabetic criteria status of those in 
G3 and G4 were confirmed by haemoglobin A1C (HbA1C) levels (< 5.7% and < 39 
mmol/mol). Patients with diabetes were on a range of treatments with the majority on oral 
agents (72%). Otherwise, treatments include diet only (12%), insulin and oral agents (8%), 
insulin only (2%), GLP-1 and insulin (2%), no treatment (2%) and other (2%). 
 
(iv) Cardiovascular Participants 
For Group1 and 3, clinical evidence of CVD had to be a minimum of one of the following: 
CHD, stroke and/or PVD. Further description and criteria can be seen in Table 5-2. A 
breakdown is for CVD groups G1 and G3 are shown in Table 5-3. 
The majority of patients had a CHD event (75-79%) with a minority having stroke and 
PVD ( > 20%) as a cardiovascular complication. From both groups, patients mostly had 
single cardiac event (93%, n = 37) with 8% (n = 3) of CVD patients having two 
complications. The majority of the study populations had underlying hypertension (85%, n 
= 34). Further breakdown is shown in Table 5-3. 
  
100 
 
Table 5-2 Cardiovascular inclusion criteria for SUMMIT participants: G1 and G3 were 
required to have clinical evidence of at least one of the following (I-III) to satisfy CVD criteria 
 Cardiovascular Inclusion Criteria Description 
I Coronary Heart Disease (CHD) 
Non-fatal acute myocardial infarction, 
hospitalised acute coronary syndrome, 
resuscitated cardiac arrest, coronary 
artery bypass graft (CABG) or any 
coronary revascularisation procedure 
II Stroke 
Non-fatal stroke and transient 
ischaemic attack (TIA) confirmed by 
specialist (excluding TIA not 
confirmed by specialist, haemorrhagic 
stroke, and stroke associated with a 
primary haematological disease e.g 
leukaemia, polycythaemia, blood 
disease, tumour, trauma, or surgical 
procedures) 
III 
Peripheral Vascular Disease 
(PVD) 
Ankle-brachial index (ABI) < 0.9 with 
intermittent claudication, or abnormal 
toe systolic pressure, pulse volume 
recordings, transcutaneous oxygen 
measurements or vascular imaging or 
prior corrective surgery, angioplasty or 
above ankle amputation 
.  
Table 5-3 Type of CVD diagnosis in patients: A breakdown of the diagnosed CVD participants 
from Groups 1 and 3. Data presented as % (n) of total participants.    
Cohorts with CVD 
Group 1 
(CVD and T2DM) 
Group 3 
(CVD only) 
CHD 74% (17) 79% (15) 
PVD 17% (4) 10% (2) 
Stroke 19% (5) 16% (3) 
Acute MI 48% (11) 68% (13) 
CABG 18% (4) 16% (3) 
Cardiac Arrest 8% (2) 16% (3) 
Hypertension 78% (18) 84% (16) 
PCI 22% (5) 42% (8) 
TIA 0% (0) 13% (1) 
Unstable Angina 26% (6) 31%(6) 
T2DM 100% (23) 0% (0) 
Abbreviations: CHD: Chronic Heart Disease, PVD: Peripheral Vascular Disease, Acute MI: Acute 
Myocardial Infarction, CABG: Coronary Artery Bypass Surgery, PCI: Percutaneous Coronary 
Intervention, TIA: Transient Ischaemic Attack. 
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5.3.3 MR Clinical Protocol for SUMMIT 
 
MRI study protocol was designed to assess cardiac and aortic function with whole body 
imaging. Full details of the setup are described in full in Methods and Materials (3.2) and 
full MRI SUMMIT protocol can be found in Appendix A. Full LV analysis was completed 
for these patients by experienced MRI segmenters (SM, SD) and aortic flow quantification 
was completed using the optimised transit-time methods as described in Chapter 3 (DC). 
5.3.4 Statistical Analysis  
Descriptive statistics was used for the analysis of the demographic and clinical features of 
the cohorts with data expressed as mean ± SD. All data was tested for equality of variance 
by using Levene’s test of homogeneity, where P > 0.05 indicated normal parametric data. 
An outlier labelling rule was applied to data returning an extreme outlier (> 3σ). 
Between group differences were calculated using an ANOVA test, and a Fisher’s LSD 
post-hoc adjustment was applied for multi-comparisons with both PWV and LV function.  
 
Pearson’s correlations were used to assess independent associations with PWV and LV 
function with population risk factors. In these analysis, dummy variables were used for 
gender (female = 0, male = 1) and smoking (0 = non-smoker, 1 = ex-smoker, 2 = smoker) 
and significance was assumed at P < 0.05. 
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5.4 Results 
5.4.1 Demographics and Baseline Characteristics 
Baseline characteristics are shown in Table 5-4. There was no significant difference 
regarding age, body weight, BMI, SBP or DBP across the groups. However gender, BSA, 
waist circumference and hypertension were found to differ significantly (P < 0.05). BMI 
and BSA were found to be marginally higher in the T2DM groups (G1 and G2) and 
hypertension and males were more predominant in the CVD groups (G1 and G3).  
Table 5-4 Anthropometric data for participants: Data presented as mean value ± SD for each 
Groups 1 - 4. 
 
Group 1 
CVD & T2DM 
Group 2 
T2DM 
Group 3 
CVD 
Group 4 
Controls 
Age 65 ± 7 61 ± 9 66 ± 8 63 ± 8 
Gender 19M:4F 17M:12F 14M:5F 6M:13F 
Sample size 23 29 19 19 
Body weight (kg) 90.3 ± 13.4 88.1 ± 17.7 83.4 ± 14.3 78.0 ± 14.9 
BMI (m
2
) 31.3 ± 4.5 30.5 ± 5.3 29.8 ± 3.9 28.4 ± 3.8 
BSA (kg/m
2
) 2.0 ±0.2 2.0 ± 0.3 1.85 ± 0.1 1.9 ± 0.3 
Systolic blood pressure 
(mmHg) 
136  ± 12 136 ± 14 136 ± 19 129 ± 9 
Diastolic blood pressure 
(mmHg) 
75 ± 8 78 ± 8 76 ± 8 77 ± 9 
Pulse Pressure 67 ± 14 68 ± 12 65 ± 9 54 ± 9 
Hypertension 78% (18) 48% (14) 84% (16) 26% (5) 
T2DM Duration (years) 9.3 ± 4.9 7.7 ± 5.8 0 0 
Abbreviations: T2DM: Type-2 Diabetes Mellitus, BMI: Body Mass Index: body weight (kg)/ height
2 
(m), 
BSA: Body Surface Area Dubois and Dubois formula 
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5.4.2 Cardiac MR Assessment 
Of the original 146 recruited into the MRI study, 23 participants opted not to continue with 
PWV scanning or retiring the scan before completion (Figure 5-1). In addition, the first 22 
patients studied were subsequently excluded due to change of protocol and a further 8 scans 
were judged uninterpretable, due to cardiac triggering errors, poor traces or unacceptable 
image quality. This resulted in a final total of 90 participants (65%) to undergo PWV 
assessment. 
5.4.3 Aortic PWV in SUMMIT Groups  
An outlier labelling rule was applied to the data returning an extreme outlier (> 3 σ) in G2. 
Before removal of outliers, G2 mean PWV was 8.4 ± 4.8 ms
-1
 with n = 29 subjects.  
Levene’s test verified the equality of variances in the samples, P > 0.05, thus the data is of 
normal distribution. One other patient was excluded from G1 (leaving n = 22) as the LV 
data was of poor image quality. The PWV results for the final 88 participants are shown in 
the table below.  
 
Table 5-5 Aortic PWV means ± SD for each group: The mean PWV was found to be 
significantly different between groups  
CMR data 
Group 1 
CVD & T2DM 
Group 2 
T2DM 
Group 3 
CVD 
Group 4 
Controls 
ANOVA 
Sig. 
PWV (ms
-1
) 8.7 ± 2.8, n =22 7.5 ± 2.3, n =28 8.9 ± 3.6, n =19 6.7 ± 1.8, n =19 *P = 0.04 
 
  
104 
 
 
Statistical Analysis of Aortic PWV between Groups  
The means and SD of aortic PWV are presented in Table 5-5, in which a significant 
difference was found between groups (ANOVA, P = 0.04).   
Post-hoc LSD test revealed that groups with diagnosed CVD (G1 and G3) were 
significantly greater than controls, G4 (P = 0.02, P = 0.02 respectively). No difference in 
PWV was found between T2DM (G2) or control groups (Figure 5-2) or between either the 
CVD groups (G1 vs. G3), (P > 0.05).  
 
 
 
Figure 5-2 Box Plot of mean aortic PWV across groups: The mean PWV was found to be 
significantly higher in CVD groups (G1, G3) than controls (G1), (ANOVA, P < 0.05). 
 
 
  
105 
 
5.4.4 Left Ventricle Function in SUMMIT Groups  
The LV parameters were calculated for each of the groups and tested for equality of 
variances (Levene’s test, P > 0.05). Due to poor image quality, one participant was 
excluded from G1. The results for the final 88 participants are displayed in Table 5-6. A 
combination of both absolute (also referred to as indexed) values for LV function (EF, 
LVM-A) and LV function normalised to BSA were analysed (EDV-N, ESV-N, SV-N and 
LVM-N).  
 
Table 5-6 Box Plot of mean LV parameters across groups: The mean PWV was found to be 
significantly higher in CVD groups (G1, G3) than controls (G1), *(ANOVA, P < 0.05) 
CMR data  
Group 1 
CVD & T2DM 
Group 2 
T2DM 
Group 3 
CVD 
Group 4 
Controls 
ANOVA  
Sig. 
EF (%) 63.4 ± 9.8 65.1 ± 8.4 64.1 ± 12.0 65.3 ± 7.9 NS, P = 0.91  
EDV-N (ml) 72.5 ± 11.5 69.32 ± 13.9 76.1 ± 23.6 68.78 ± 9.1 NS, P = 0.40 
ESV-N (ml) 27.0 ±9.9 24.6 ± 9.7 28.9 ± 19.0 24.1 ± 7.0 NS, P = 0.55 
SV-N (ml) 45.5 ± 8.0 44.7 ± 8.4 47.2 ± 9.3 44.7 ± 6.9 NS, P = 0.73 
LVM-N (gm
-2
) 62.5 ± 10.4 56.8 ±12.0 61.5 ± 10.9 51.5 ± 5.3 *P = 0.004 
LVM-A (g)  125.4 ± 24.2 114.1 ± 32.1 117.5 ± 23.2 95.9 ± 18.22 *P = 0.005 
Abbreviations: EDV-N: Normalised End Diastolic Volume, ESV-N: Normalised End Systolic Volume, SV-
N: Normalised Stroke Volume, LVM-N: Normalised Left Ventricular Mass, LVM-N: Absolute Left 
Ventricular Mass. 
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Statistical analysis of LV function between groups  
There was no significant difference was seen between EF, EDV, ESV, SV between the 4 
groups, (ANOVA, P > 0.05).  
 
LVM was found to be different across the groups; LVM-N, (ANOVA, P = 0.004) and 
LVM-A, (ANOVA, P = 0.005). Post-hoc LSD comparisons revealed that G1 and G3 (CVD 
and with or without T2DM) had significantly higher LVM-N than controls, G4 (P = 0.001, 
P = 0.003, respectively). Similarly to PWV, T2DM participants (G2) did not differ 
significantly from the control group (G4), (ANOVA, P = 0.08) and the CVD groups (G1, 
G3) did not differ from each other (Figure 5-3).  
 
In the case of LVM-A, all patient groups (G1, G2 and G3) were found to have significantly 
higher LVM than control group, (post-hoc LSD, P < 0.05) (Figure 5-4). However, there no 
significant difference between patient groups (G1, G2 and G3), (post-hoc LSD, P > 0.05). 
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Figure 5-3 Box-plot of normalised LVM across groups: The mean LVM-N was found to be 
significantly higher in CVD groups (G1, G3) than controls (G1), (ANOVA, P < 0.05). 
 
 
Figure 5-4 Box-plot of absolute LVM across groups: The mean LVM-N was found to be 
significantly higher in CVD groups (G1, G3) than controls (G1), (ANOVA, P < 0.05). 
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5.4.5 Aortic PWV and Left Ventricular Function   
 
No significant correlation was found between PWV and LV parameters (Pearson 
correlation, P > 0.05, 2-tailed). Increased aortic PWV showed a negative trend with EF (ρ = 
-0.13, P = 0.20), EDV (ρ = -0.28, P = 0.22), ESV (ρ = -0.10, p=0.65), SV (ρ = -0.29, P = 
0.18). For LVM, it correlated positively with PWV (ρ = -0.04, P=0.87) and is shown in 
Figure 5-5.  
 
Figure 5-5 Scatter-plot of the relationship between aortic PWV and (i) normalised LVM and 
(ii) absolute LVM: PWV was plotted against LVM-N and LVM-A, however no significant 
correlation was found (Pearson correlation, P > 0.05).  
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5.4.6 Reclassification of Groups for either T2DM or Cardiovascular Disease 
For part II of analysis, the original classification of their SUMMIT grouping will be used 
(G1 to G4) as shown in Table 5-7. New groups were also adapted into composite groups in 
respect to the presence or absence of T2DM and with or without CVD for analysis, groups; 
G5, G6, G7 and G8.  
Table 5-7 Reclassification of SUMMIT groups: Original SUMMIT grouping are shown from G1 
to G4. *G5 to G8 are new composite groups used in subsequent analysis.  
Groups Group description Group size, n 
Group 1 Participants with T2DM with CVD (G1) n = 22 
Group 2 Participants with T2DM without CVD (G2) n = 28 
Group 3 Participants with no T2DM and with CVD (G3) n = 19 
Group 4 Participants with no T2DM without CVD (G4) n = 19 
*Group 5 All participants with T2DM with and without CVD (G5) n = 50 
*Group 6 All participants with no T2DM with and without CVD (G6) n = 38 
*Group 7 All participants with CVD, with and without T2DM (G7) n = 41 
*Group 8 All participants without CVD, with and without T2DM  (G8) n = 47 
 
The following relationships will be investigated using groups as defined in Table 5-7:  
(i)  Aortic PWV and T2DM 
(ii)  Left Ventricular Function and T2DM 
(iii) Aortic PWV  and Duration of T2DM  
(iv) Left Ventricular Function and Duration of T2DM  
(v)  Aortic PWV and CVD  
(vi) Left Ventricular Function and CVD 
  
110 
 
5.4.6 (i) Aortic PWV and T2DM 
Using the reclassified G5, the presence of T2DM was investigated in terms of PWV. No 
significant relationship was found between T2DM population (G5: 8.06 ± 2.69 ms
-1
) 
compared to the non-T2DM (G6: 7.85 ± 3.01 ms
-1
), (unpaired t-test, P > 0.72).This is 
shown in Table 5-8 below and Figure 5-6.   
Table 5-8 Mean aortic PWV of patients with and without T2DM: PWV was compared for 
T2DM (G5, G2, G1) versus non-T2DM controls (G6, G4, G3), irrespective of presence of CVD. No 
significant difference was found (unpaired t-test, P > 0.05). 
T2DM Groups PWV ms
-1
 Non-T2DM Group
 
PWV ms
-1 
P-value 
G5: 
 
All T2DM with 
and without CVD 
8.06 ± 2.69, n = 50 G6: 
All non-T2DM 
with and 
without CVD 
7.85  ± 3.01, n = 38 NS, P = 0.72 
G2: 
T2DM with no 
CVD 
7.58 ± 2.3, n = 28 G4: 
Non-T2DM 
with no CVD 
6.77 ± 1.8, n = 19 NS, P = 0.28 
G1: T2DM with CVD 8.68 ± 2.8, n = 23 G3: 
Non-T2DM 
with CVD 
8.93 ± 3.6, n = 19 NS, P = 0.80 
 
 
Figure 5-6 Scatter-plot of PWV and T2DM: Relationship of PWV with T2DM (G5, G2, G1) and 
without T2DM (G6, G4, G3), no significant difference was found (unpaired t-test, P > 0.05) 
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5.4.6 (ii) Left Ventricular Function and T2DM  
 
No significant difference between mean LVM-N was found between T2DM (G5: 59.3 ± 
11.6 gm
-2
) and non- T2DM G6: (56.4 ± 9.9 gm
-2
), (unpaired t-test, P = 0.23) as shown in 
Table 5-9. 
In contrast, LVM-A was found to be significantly higher in T2DM (G5: 119.1 ± 29.2 g
-2
) 
compared to the non-T2DM population (G6: 106.7 ± 23.3 g
-2
), (unpaired t-test, P = 0.03). 
This is shown in Table 5-10 and Figure 5-7.   
Table 5-9 Mean LVM-N of patients with and without T2DM: LVM-N was compared for T2DM 
(G5, G2, G1) versus non-T2DM controls (G6, G4, G3), irrespective of presence of CVD. No 
significant difference was found (unpaired t-test, P > 0.05). 
T2DM Groups LVM-N (gm
-2
) Non-T2DM Group
 
LVM –N (gm
-2
)
 
P-value 
G5: 
 
All T2DM with 
and without CVD 
59.3 ± 11.6, n = 50 G6: 
All non-T2DM 
with and 
without CVD 
56.4 ± 9.9, n = 38 NS, P = 0.23 
G2: 
T2DM with no 
CVD 
56.8 ±12.0, n = 28 G4: 
Non-T2DM 
with no CVD 
51.5 ± 5.3, n = 19 NS, P = 0.07 
G1: T2DM with CVD 62.5 ± 10.4, n = 23 G3: 
Non-T2DM 
with CVD 
61.5 ± 10.9, n = 19 NS, P = 0.76 
 
Table 5-10 Mean LVM-A of patients with and without T2DM: PWV was compared for T2DM 
(G5, G2, G1) versus non-T2DM controls (G6, G4, G3), irrespective of presence of CVD. No 
significant difference was found (unpaired t-test, P > 0.05). 
T2DM Groups LVM Abs (g) Non-T2DM Group
 
LVM Abs (g)
 
P-value 
G5: 
 
All T2DM with 
and without CVD 
119.1± 29.2 , n= 50 G6: 
All non-T2DM 
with and 
without CVD 
106.7 ±  23.3, n=38 *P=0.04 
G2: 
T2DM with no 
CVD 
114.1 ± 32.1, n=28 G4: 
Non-T2DM 
with no CVD 
95.9 ± 18.2, n=19 *P=0.03 
G1: T2DM with CVD 125.4 ± 24.2, n=23 G3: 
Non-T2DM 
with CVD 
117.5 ± 23.2, n=19 NS, P=0.29 
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Figure 5-7 Scatter-plot of (i) normalised LVM, (ii) absolute LVM and T2DM: Mean LVM-N 
was not significantly different between T2DM and non-T2DM (unpaired t-test, P > 0.05). However 
a significant relationship was found between mean LVM-N (unpaired t-test, P < 0.05) 
 
The rest of the LV parameters also did not show significant relationship between T2DM 
and non-T2DM population. EF (64.3 ± 10.0 vs. 64.7 ± 9.0%, P = 0.74), EDV (70.7 ± 12.9 
vs. .72.4 ± 18.0 ml, P = 0.21) and SDV (25.6 ± 9.8 vs. 26.5 ± 14.3 ml, P = 0.31) and SV 
(45.1 ± 8.11 vs. 45.9 ± 8.2 ml, P = 0.34) were similar in both groups. 
113 
 
5.4.6 (iii) Aortic PWV and duration of T2DM  
The duration of T2DM was defined from the date of clinical diagnoses. Duration of T2DM 
did not show a significant relationship with PWV (Pearson’s correlation, P = 0.80).   
Likewise, when the duration was divided into tertiles (< 5 years, 6 – 10 years and < 11 
years), no significant difference was seen with mean PWV (unpaired t-test, P > 0.05). 
Results are shown in Table 5-11 and in Figure 5-8. 
Table 5-11 Aortic PWV and duration of T2DM with and without CVD: Duration of T2DM 
ranged from early onset >1 year to 14 years. For this analysis, T2DM duration was divided into 3 
tertiles (< 5 years, 6 – 10 years and < 11 years). No significant difference was found between 
groups (unpaired t-test, P > 0.05).  
Factors 
G1: CVD and T2DM  
PWV ms
-1 
G2: T2DM  
PWV ms
-1
 
P-value 
< 5 years 8.85 ± 2.7, n = 6 7.10 ± 1.3, n = 10 NS, P = 0.10 
6 – 10 years 8.89 ± 1.4, n = 4 8.07 ± 2.6, n = 10 NS, P = 0.56 
> 11 years 7.75 ± 2.6, n = 12 7.57 ± 3.0, n = 8 NS, P = 0.89 
 
 
Figure 5-8 Aortic PWV for T2DM duration with and without CVD (i) years and (ii) tertiles: 
No significant mean difference was found between PWV and duration of T2DM, (unpaired t-test, P 
> 0.05).  
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5.4.6 (iv) Left Ventricular Function and duration of T2DM  
Duration of T2DM also did not show a significant relationship with any of the LV 
parameters either absolute or normalised LVM (Pearson’s correlation, P = NS). Likewise, 
when the duration was divided into tertiles, neither group (G1 and G2) showed any effect 
(t-test, P > 0.05), results are shown in Table 5-12 and Figure 5-9.  
Table 5-12 LVM and duration of T2DM with and without CVD: Duration of T2DM ranged 
from early onset >1 year to 14 years. This table shows 3 tertiles (< 5 years, 6 – 10 years and > 11 
years). No significant difference was found between groups (unpaired t-test, P > 0.05). 
Factors 
G1: CVD and T2DM  
LVM-N (gm
-2
)
 
G2: T2DM  
LVM-N (gm
-2
) 
P-value 
< 5 years 133.9  ± 37.2, n = 6 107.7 ± 30.4, n = 10 NS, P = 0.15 
6 – 10 years 123.5 ± 16.1, n = 4 108.7 ± 31.0, n = 10 NS, P = 0.39 
> 11 years 120.9 ± 20.0, n = 12 128.9 ± 34.8, n = 8 NS, P = 0.49 
 
 
Figure 5-9 LVM-N for T2DM duration with and without CVD (i) years and (ii) tertiles: No 
significant mean difference was found between PWV and duration of T2DM, (unpaired t-test, P > 
0.05) 
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5.4.6 (v) Aortic PWV and CVD 
Overall, a significantly increased PWV was found in patients with CVD compared to 
controls (G7: 8.80 ± 3.19 vs. G8: 7.25 ± 2.2 ms
-1
), (unpaired t-test, P < 0.05). Of the CVD 
group, patients with CHD and PVD show a significantly higher PWV than control 
participants, although it should be noted that PVD had a smaller sample size compared to 
CHD (n = 6 vs. n = 32). PWV in patients with stroke did not differ from controls (7.94 ± 
1.54 vs. 7.25 ± 2.2 ms
-1
, P = 0.36). The mean PWV in the CVD patient groups are 
displayed in Table 5-13.  
 
Table 5-13 Aortic PWV in patients with CVD: Mean PWV for all CVD, CHD, PVD were found 
significantly higher than compared to non-CVD controls (unpaired t-test,*P < 0.05, **P < 0.005). 
PWV in stroke was not found to be significantly changed (P > 0.05). 
Factors CVD PWV ms
-1 
Non-CVD PWV ms
-1
 P-value 
All CVD 8.80 ± 3.19, n = 41 7.25 ± 2.2, n = 47 *P = 0.009 
CHD 8.88 ± 3.49, n = 32 7.25 ± 2.2, n = 47 *P = 0.050 
PVD 10.68 ± 2.99, n = 6 7.25 ± 2.2, n = 47 *P = 0.005 
Stroke 7.94 ± 1.54, n = 8 7.25 ± 2.2, n = 47 NS, P = 0.360 
Abbreviations: PWV: Pulse Wave Velocity, CHD: Chronic Heart Disease, PVD: Peripheral Vascular Disease, 
NS: Not Significant  
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Figure 5-10 Aortic PWV in patients with CVD: Mean PWV for all CVD, CHD, PVD were 
found significantly higher than compared to non-CVD controls (unpaired t-test,*P < 0.05, **P < 
0.005). PWV in stroke was not found to be significantly changed (P > 0.05) 
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5.4.6 (vi) Left Ventricle Function and CVD 
 
For LV function, no significance was found with CVD and EF, EDV, ESV, and SV. LVM 
(both absolute and normalised) was found significantly higher in patients with CVD 
compared to controls without CVD, irrespective of T2DM (detailed for LVM-N in Table 
5-14, and LVM-A in Table 5-15 and Figure 5-11).  
 
For patients with CHD, LVM was significantly different as was EDV (G7 vs. G8; 148.2 ± 
30.7 vs. 133.1 ± 27.9 ml P = 0.03), Figure 5-11. Patients with PVD and stroke, showed an 
elevated LVM, although they did not reach significance (ANOVA, P = 0.08, P > 0.05).  
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Table 5-14 LVM-N in patients with CVD: Mean LVM-N for all CVD and CHD were 
significantly higher than non-CVD controls (unpaired t-test, **P < 0.005). LVM-N for PVD and 
stroke was not found to be significantly changed (P > 0.05).  
Factors CVD LVM-N gm
-2 
Non-CVD LVM-N gm
-2
 P-value 
All CVD 61.9  ± 10.3, n = 41 54.7 ± 10.4, n = 47 **P = 0.001 
CHD 61.6 ± 10.2, n = 32 54.7 ± 10.4, n = 47 **P = 0.005 
PVD 62.6 ± 7.8, n = 6 54.7 ± 10.4, n = 47 NS, P = 0.08 
Stroke 7.94 ± 1.54, n = 8 54.7 ± 10.4, n = 47 NS, P = 0.06 
Abbreviations: CHD: Chronic Heart Disease, PVD: Peripheral Vascular Disease, NS: Not Significant  
 
 
Table 5-15 LVM-A in patients with CVD: Mean LVM-A for CVD, CHD, PVD were significantly 
higher than non-CVD controls (unpaired t-test, **P < 0.005). LVM-A for PVD and stroke was not 
found to be significantly changed (P > 0.05). 
Factors CVD LVM-N gm
-2 
Non-CVD LVM-N gm
-2
 P-value 
All CVD 121.7  ± 10.3, n = 41 106.7 ± 29.1, n = 47 *P = 0.009 
CHD 121.5 ± 10.2, n = 32 106.7 ± 29.1, n = 47 *P = 0.016 
PVD 126.2  ± 26.9, n = 6 106.7 ± 29.1, n = 47 NS, P = 0.13 
Stroke 118.8 ± 36.8, n = 8 106.7 ± 29.1, n = 47 NS, P = 0.30 
Abbreviations: CHD: Chronic Heart Disease, PVD: Peripheral Vascular Disease, NS: Not Significant  
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Figure 5-11 LV parameters with and without CVD: Mean differences were tested for all the LV 
parameters. A significant difference was found between LVM (ANOVA, *P < 0.05, ** P < 0.005). 
 
Figure 5-12 (i) Absolute and (ii) normalised LVM with and without CVD: Mean LVM was 
significantly increased for all CVD and CHD (ANOVA, *P < 0.05, ** P < 0.005).  
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5.4.7 SUMMIT Population Factors  
Factors associated with Aortic PWV  
Population factors associated with aortic PWV were evaluated by Pearson’s correlation 
analysis (Table 5-16). Increased aortic PWV was associated positively with age, systolic 
BP and hypertension. No significant relationships were found between gender, waist to hip 
ratio, smoking, pulse pressure, and diastolic BP, height or BMI.  
Table 5-16 Multiple correlation analysis of factors associated with aortic PWV: PWV was 
found to be significantly correlated with age, systolic BP and hypertension, (Pearson’s correlation, 
*P < 0.05, **P < 0.005) 
Factors Pearson Correlation (ρ)
 
P-value 
Age (years) 0.420 **P < 0.001 
Gender (m/f) 0.726 NS, P = 0.73 
Height (m) -0.022 NS, P = 0.84 
BMI (kgm
-2
) -0.107 NS, P = 0.33 
Waist to hip ratio 0.081 NS, P = 0.46 
Smoking (y/n) 0.075 NS, P = 0.11 
Pulse pressure (mmHg) 0.002 NS, P=0.98 
Systolic BP 0.401 **P < 0.001 
Diastolic BP 0.060 NS, P = 0.57 
Hypertension 0.236 *P = 0.036 
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Factors Associated with Normalised LVM  
Population factors associated with LVM-N were evaluated by Pearson’s correlation 
analysis (Table 5-17). LVM-N was significantly positively associated with height, waist to 
hip ratio and hypertension. A significant negative correlation was found with gender, 
indicating that males have higher LVM-N than females. No significant relationships were 
found between age, smoking, systolic and diastolic BP. Interestingly, BMI was not found to 
be significant positive correlation in LVM-N compared to LVM-A. This may be the result 
of normalising the LVM-N with BSA.  
Table 5-17 Multiple correlation analysis of factors associated with LVM-N: LVM-N was found 
to be significantly correlated with height, waist to hip ratio, hypertension and gender, (Pearson’s 
correlation, *P < 0.05, ** P < 0.005). 
Factors Pearson Correlation (ρ)
 
P-value 
Age (years) 0.123 NS, P = 0.26 
Gender (m/f) -0.577 **P  < 0.001 
Height (m) 0.368 **P  < 0.001 
BMI (kgm
-2
) 0.059 NS, P = 0.59 
Waist to hip ratio 0.385 **P  < 0.001 
Smoking (y/n) 0.140 NS, P = 0.20 
Pulse pressure (mmHg) -0.144 NS, P = 0.19 
Systolic BP 0.196 NS, P = 0.07 
Diastolic BP 0.068 NS, P = 0.89 
Hypertension 0.363 **P = 0.001 
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Factors Associated with Absolute LVM  
Population factors associated with LVM-A were evaluated by Pearson’s correlation 
analysis (Table 5-18). LVM-A was significantly positively associated with height, BMI, 
waist to hip and hypertension. A significant negative correlation was found with gender, 
indicating that males have higher LVM than females. No significant relationships were 
seen with age, smoking, systolic and diastolic BP or pulse pressure.  
 
Table 5-18 Multiple correlation analysis of factors associated with LVM-A: LVM-A was found 
to be significantly correlated with height, BMI, waist to hip hypertension and gender, (Pearson’s 
correlations, *P < 0.05, ** P < 0.005). 
Factors Pearson Correlation (ρ)
 
P-value 
Age (years) 0.101 NS, P = 0.35 
Gender (m/f) -0.669 **P < 0.001 
Height (m) 0.622 **P < 0.001 
BMI (kgm
-2
) 0.276 *P = 0.01 
Waist to hip ratio 0.523 **P < 0.001 
Smoking (y/n) 0.072 NS, P = 0.50 
Pulse pressure (mmHg) -0.085 NS, P = 0.44 
Systolic BP 0.142 NS, P = 0.19 
Diastolic BP 0.027 NS, P = 0.53 
Hypertension 0.336 **P = 0.001 
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5.4.7 (i) Age Related Variation in PWV 
PWV has been shown to increase with vascular aging (Rose et al. 2010). A strong 
relationship between PWV and age was seen across all participants (P < 0.001). Although 
age has significant effect in all groups, it could be assumed that the effects of age on arterial 
stiffening is equal across all groups as no significant difference was found between groups 
regarding age (baseline characteristics, Table 5-4). Interestingly, a higher correlation was 
found in the patient groups (G1, G2 and G3) than the controls (G4) as displayed in Figure 
5-13.  
 
 
Figure 5-13 Regression analysis of aortic PWV and age: A significant correlation was seen 
between PWV and age (Pearson’s correlation, P < 0.001). 
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5.4.7 (ii) Hypertension and Aortic PWV 
 
The following Table 5-19 summarises PWV in hypertensive patients and normotensive 
individuals. Hypertensive was associated with a significantly raised PWV (unpaired t-test, 
P = 0.03). Although this relationship was not identified in the groups individually, 
(unpaired t-test, P > 0.05).  
Table 5-19 Aortic PWV for hypertensive and normotensive participants: Aortic PWV was 
significantly elevated in hypertensive individuals compare to normotensives, (unpaired t-test, P = 
0.03). 
 
Hypertensive
 
Normotensive P-value 
All Groups 8.49  ± 3.1, n=53 7.17 ± 2.0, n=35 *P = 0.03 
CVD + T2DM (G1) 8.86 ± 2.9, n=18 7.61 ± 2.5, n=4 NS, P = 0.54 
T2DM (G2) 7.61 ± 2.5, n=14 7.54 ± 2.2, n=14 NS, P = 0.94 
CVD (G3) 9.15 ± 3.8, n=16 7.73 ± 2.1, n=3 NS, P = 0.55 
Controls (G4) 7.59 ± 2.6, n=5 6.47 ± 1.46, n=14 NS, P = 0.25 
 
 
Figure 5-14 Regression analysis of aortic PWV and hypertension and normotensive 
participants.   
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5.4.7 (iii) Smoking Status and Aortic PWV 
 
No significant relationship was found between smoking and PWV, (Pearson correlation, P 
= 0.78). Although not significant, PWV was found to be slightly higher in ex-smokers (8.20 
± 2.9, n = 39) and smokers (8.37 ± 3.9, n = 8) compared to non-smokers (7.81 ± 2.4, n = 
38). The majority of non-smoking participants were in the T2DM and control group (G2, 
G4), the majority of ex-smokers were participants with CVD with and without T2DM (G1, 
G3). Out of all the groups, only 9% were current smokers.  
 
 
5.4.7 (iv)  Gender and Aortic PWV 
 
Gender showed no significant relationship with aortic PWV, Pearson correlation, P = 0.73. 
Although, it was found to be highly significant factor for LVM (Pearson correlation, P < 
0.001).  
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Table 5-20 Summary of key findings in Chapter 5 
Investigation Key Results 
I. Summit Groups Analysis (5.4.1 – 5.4.5) 
Demographics and baseline characteristics  
 
 
 No significant differences were seen regarding age, 
body weight, BMI, SBP, DBP, (ANOVA, P > 0.05). 
 Gender, BSA, waist circumference and hypertension 
differed significantly, (ANOVA, P < 0.05). 
 
Aortic PWV between groups  
 
 Mean PWV was found significantly differ between 
groups (ANOVA, P < 0.05). 
 Mean PWV of CVD groups (G1 and G3) were 
significantly greater than controls (G4), (post-hoc 
LSD test, P < 0.05). 
LV function between groups  
 
 No significant difference was seen between EF, 
EDV, ESV, SV between the 4 groups, (ANOVA, P 
> 0.05). 
 LVM was found to differ between the 4 groups 
(ANOVA, P < 0.005). 
 Mean LVM-N of CVD groups (G1 and G3) was 
significantly higher than controls (G4), (post-hoc 
LSD, P < 0.005), however no difference was found 
between either of the CVD groups (G1 vs. G3) or 
T2DM and controls (G2 vs. G4) (post-hoc LSD, P > 
0.05).  
 Mean LVM-A was found to be increased in all the 
patient groups (G1, G2, and G3) than controls (G4), 
(post-hoc LSD, P < 0.05). There was no difference 
between patient groups, (post-hoc LSD, P > 0.05). 
Aortic PWV and LV function   
 
 No significant correlation was found between PWV 
and LV parameters (Pearson correlation, P > 0.05). 
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II. Reclassification of Groups for either Diabetes or Cardiovascular Disease (5.4.6) 
Aortic PWV with and without T2DM  
 
 Mean PWV was not found to be significantly 
different with or without T2DM (G5 vs. G6), 
(unpaired t-test, P > 0.05).   
LV Function with and without Diabetes  
 
 Mean LVM-N was not found to be significantly 
different with or without T2DM (G5 vs. G6), 
(unpaired t-test, P > 0.05). 
Aortic PWV and LVM and duration of 
T2DM 
 
 No significant correlation was found between PWV 
and LV parameters with T2DM duration (Pearson 
correlation, P > 0.05). 
Aortic PWV and CVD 
 
 Mean PWV was found to be significantly different 
with or without CVD (unpaired t-test, P < 0.05).   
Left Ventricle Function and CVD 
 
 Mean LVM was found to be significantly different 
with or without CVD (unpaired t-test, P < 0.05).   
III. Population factors (5.4.7 )  
Factors associated with Aortic PWV  
 
 PWV was associated positively with age, systolic 
BP and hypertension (Pearson correlation, P < 
0.05). 
 No significant relationships were found between 
gender, waist to hip ratio, smoking, pulse pressure, 
and diastolic BP, height or BMI (Pearson 
correlation, P > 0.05). 
Factors associated with LV Function  
 
 For LVM-N, significant negative correlation was 
found with gender, indicating that males have higher 
LVM than females (P < 0.05), no significant 
relationships were found between age, smoking, 
systolic and diastolic BP (P > 0.05). 
 LVM-A was significantly positively associated with 
height, BMI, waist to hip and hypertension (P > 
0.05), a significant negative correlation was found 
with gender, indicating that males have higher LVM 
than females (P > 0.05). 
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5.5 Discussion 
 
In this study, aortic and cardiac function was evaluated by MRI in multiple cohorts of 
patients with and without T2DM, with and without the presence of CVD. Damage to the 
large arteries is a major contributor to high cardiovascular morality, with PWV proving to 
be a useful predicator of structural and functional changes of the arterial wall (Blacher et al, 
2005). The primary finding highlights PWV as a stronger marker of CVD complications 
with and without T2DM, than merely just uncomplicated diabetes.  
 
The present study differs to other MRI aortic PWV studies as it uses a heterogeneous 
complicated T2DM patient population with and without symptomatic CVD. In an 
uncomplicated T2DM group, a study by van der Meer et al. (2007) found PWV to be 
significantly increased in patients with diabetes as compared to healthy subjects. No 
significance was found in our study but this may be due to the variation in duration of 
diabetes (0 - 24 years) compared to their tighter selection criteria for diabetes duration (less 
than 5 years) and well-matched controls. However, we did see a significant increase in the 
CVD population with and without T2DM. 
 
The quantitative parameters of LV function were found to be similar across the different 
patient groups apart from LVM. As expected, it was elevated in the two CVD groups in this 
this study, with and without T2DM. No relationship was found between aortic PWV and 
LV function; although in previous studies they have stated a negative relationship with 
diastolic function and increased PWV (van der Meer et al. 2007).  
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Delayed glycemic control and prolonged duration of diabetes perilously increase 
cardiovascular risk, with a direct relationship between the risk of developing cardiovascular 
complications and increasing hyperglycemia, especially for microvascular diseases 
(UKPDS 35 study, Stratton et al, 2000) . In our study, the duration of diabetes showed no 
association with PWV or cardiac function suggesting that CVD risk does not increase 
linearly with onset of diabetes. Although, it may be argued that the clinical baseline of 
patient diagnoses may not always be the beginning of the disease and it is difficult to factor 
the effect of different treatment regimens within the size of our current study group. 
The patient groups were also analysed in terms of CVD (G1 and G3), which showed that 
irrespective of presence of diabetes, CHD and PVD have a positive relationship to PWV. 
No significance change was seen in stroke or T2DM. However, conclusive statements on 
the relationship between stroke and PVD and elevated PWV are limited due to the low 
sample size within each of these groups (n = 6 and n = 8, respectively). Further work in 
Chapter 7 will interrogate the interaction of PWV and PVD using multi-slice PWV.  
 
It has been shown in normal volunteer studies that LV parameters can be influenced by age, 
BSA and gender. (Maceria et al 2006) In our study, the cardiac assessment, LVM and CO 
showed a significant relationship with PWV, while ESV, EDV and EF showed no 
correlation. These findings are comparable to previously study findings (Aquaro et al. 
2013).  
Vascular ageing results in dilatation and arterial stiffening due to elastin fibres weakening 
and mechanical stress over time. A linear relationship was found between ageing and PWV 
in a healthy population. In the patient groups, a linear relationship was also found but it was 
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significantly higher than the non-disease population. Interestingly, the T2DM cohort (G2) 
showed a similar relationship to PWV as the other two patient groups with CVD, (G1, G3). 
This may indicate that even though the T2DM cohort did not show significantly higher 
PWV than the healthy population, it may still have a slightly accelerated progression of 
arterial stiffness with age.  
 
An overall increase in aortic stiffness was seen but it needs to be determined if stiffening 
can be specific to regional areas along the aorta. In a study by Hickson et al. (2010), age 
was shown to differentially affect regional aortic stiffness, with the greatest difference in 
the distal aorta in a healthy population. The PWV technique applied in this study is limited 
to only assessing three sites of the aorta; ascending aortic arch, descending aortic arch and 
the abdominal aorta. Therefore, we were unable to assess the effect of disease duration or 
progression with localised aortic stiffening. Another limitation due to the small cohorts, is 
the difficultly separating the effects of ageing on the vascular system from disease 
pathology.  
 
Further development of this technique will involve application of a multi-site PWV 
technique, validated in a healthy population and applied to a patient population of PVD. 
This population was selected as it was underpowered in this study and there was greater 
availability of this patient group in comparison to CHD and stroke. Outcomes of these 
results are discussed in Chapters 6 and Chapter 7.  
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This study has shown that aortic PWV increases with hypertension and CVD. Although 
arterial stiffness is well established in T2DM and CVD, this study differed as the 
heterogeneous cohorts ranged from a healthy population, to patients with T2DM through to 
the later complicated T2DM and CVD. 
 
Epidemiological studies highlight an increased cardiovascular risk in diabetic patients 
which is enhanced when in combination with other CVD risk factors such as hypertension, 
dyslipidemia, obesity and glucose intolerance. (Ong et al. 2007; Juutilainen et al. 2005) 
Hypertension is an established risk factor of CVD, and often shares a significant overlap 
with diabetes and systemic vascular diseases (Sowers et al. 2001). Regardless of diabetes, 
CVD or being a healthy participant, all patients with hypertension showed a significantly 
higher PWV than normotensive patients. The elevated aortic PWV correlates with both 
hypertensive status and presence of clinically apparent arterial disease, independent of one 
another and can support its importance as a maker of cardiovascular risk in hypertensive 
patients as seen in larger epidemiological studies (Blacher et al. 1999). Hypertension and 
diabetes are both associated with increased aortic PWV. However, the association of 
hypertension with diabetes may obscure the degree to which diabetes rather than 
hypertension contributes to an elevated PWV.  
 
Conversely, smoking has been shown to exacerbate cardiovascular risk particularly in the 
case of PVD and CHD (Price 1999). In our cohorts, patients were divided into non-
smokers, ex-smokers or current smokers but failed to show a significant correlation with 
PWV.   
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The pathological mechanism linking increased aortic stiffness to cardiovascular events is 
still relatively unclear. PWV leads to an early reflected wave return and higher systolic and 
lower diastolic central pressures contributing to the rise of left ventricular workload, 
subsequent hypertrophy and a decrease in coronary perfusion (Mitchell et al. 2010). 
Previous studies have established the prognostic value of this CVD marker by means of 
cross sectional and longitudinal studies such as Framingham and the Rio de Janerio 
(Cardoso et al. 2013).  
 
We acknowledge some limitations to this study such as study design, cohort’s size, age 
distribution and gender matching. The purpose of this study was to pilot and to gain an 
experimental insight of applying different MRI imaging markers in the quest to stratify 
between disease groups. As effect size was not estimated prior recruitment, it therefore 
insufficiently powered for subgroup analysis. This was particularly reflective in the patient 
CVD subgroup analysis of both the PVD and stroke group, and it is therefore difficult to 
make a definitive conclusion. Another limitation of MRI is the contraindications, cost and 
the timely acquisitions of MRI scans which consequently limits the size of the population 
in comparison to the more time efficient and cost effective CF-PWV technique. 
 
PWV is a predictor of future fatal and non-fatal cardiovascular events in high risk diabetic 
patients over and beyond traditional cardiovascular risk factors including micro- 
macrovascular diabetes complications, metabolic control parameters and ambulatory BP 
levels (Cardoso et al. 2013). As this is a single time point cross sectional study, we are 
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unable to make comment on the prediction of future fatal and non-fatal CVD complications 
nor estimate a mortality index as previously performed in large population studies. A 
follow-up study would be interesting as a comparison for this population. 
 
Otherwise, the strengths of our study were that it was the first to implement a 
comprehensive MRI protocol in a complicated T2DM patient population with and without 
symptomatic CVD. In this study, we investigated cardiac function alongside aortic PWV 
without the need of anatomical assumptions made in other PWV assessment methods. Most 
studies to date have employed ultrasound and applanation tonometry to assess PWV or 
vascular distensibility (Cruickshank 2002). As this study used MRI in assessing aortic 
stiffness, we were able to measure a local aortic PWV and make a direct measure of aortic 
path length. A local aortic PWV may also minimises influences of peripheral arteries, 
especially as it has been postulated, that diabetes has a preferential impact on central elastic 
arteries compared to muscular peripheral arteries (Kimoto et al. 2003). 
 
 
5.6 Summary 
 
PWV is a marker of arterial stiffness and aortic and cardiac function was defined in patients 
with and without T2DM and with and without CVD using a comprehensive CMR protocol. 
PWV was assessed using flow waveforms using MRI and was found to be significantly 
higher in CVD than T2DM.   
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Arterial stiffness, through its effect on the pulse wave and central aortic pressure, may be a 
key determinant of increased cardiovascular risk but was not found to be significantly 
elevated in patients with uncomplicated T2DM.  
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 CHAPTER 6
Validation of Multi-Site PWV  
 
6.1 Introduction  
PC-MRI can interrogate blood velocity at multiple vessel regions within a single 
examination and provides a non-invasive method of estimating PWV along the entire aorta.  
The simplest method of deriving PWV from MR data is to determine the temporal shift 
between two flow waveforms, which can be achieved through-plane to the aorta, at two 
locations (typically the aortic arch and the descending aorta). This has been the most 
commonly used technique in the literature  (Ibrahim et al. 2010; van der Meer et al. 2007; 
Westenberg et al. 2011) and has been applied in Chapters 4 and 5. For the purposes of this 
chapter, it will be referred to as conventional-PWV (C-PWV). 
 
Recently, the use of more than two waveforms has been shown to result in higher PWV 
accuracy-than C-PWV, even at the expense of lower temporal resolution (Kröner et al. 
2012). To date, the use of a multi-site PWV method (MS-PWV) has been limited a to 
healthy ageing population (Rogers et al. 2001; Hickson et al. 2010) and a population with 
Marfan syndrome (Kröner et al. 2012; Westenberg et al. 2011).  
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The aim of this chapter was to estimate MS-PWV from number of sample points along the 
aorta in a cohort of young healthy volunteers and to compare it with the C-PWV technique 
and to also test the scan to scan variability of MS-PWV.   
 
6.2 Study Aims  
The aims of the research presented in this chapter are:   
i. To derive multi-slice PC-MRI data (with through-plane velocity encoding) to 
measure flow and PWV calculated over 6-8 different anatomical sites from the 
aortic arch to the renal bifurcation.   
ii. To compare MS-PWV with the two slice C-PWV method.   
iii. To determine scan to scan variation of MS-PWV by repeating the scan setup.  
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6.3 Methods 
6.3.1 Demographics and Baseline Characteristics 
For this study, a cohort of young healthy participants (YHV), under 40 years of age, were 
recruited (n = 22). They had a mean age of 29 ± 6 years and with 10 males and 12 females.   
All MR examinations were performed with setup as described in Chapter 3.  
6.3.2 Image Acquisition and Analysis 
The MRI study protocol for this study was designed to assess cardiac and aortic function 
via the C-PWV and MS-PWV method (full protocol Appendix A). The results of the LV 
cardiac function are later discussed in Chapter 7. 
 
The protocol was divided into two parts (as detailed below). When Part I was completed the 
volunteer was asked to leave the MRI table for a short break and then returned for Part II. 
The second part only acquired MS-PWV for the purpose of testing scan to scan 
repeatability.  
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Part I: 
i. Acquisition of the cine images acquired in 2 and 4 chamber orientations and a stack 
of cine images acquired in the short axis from base to apex to assess cardiac 
function.  
ii. Aortic flow quantification with C-PWV at the aortic arch and just above the renal 
bifurcation for calculation of PWV.  
iii. Multi-site aortic flow quantification (5 to 8 sites, depending on the length of the 
aorta) for calculation of MS-PWV.  
 
Part II 
i. Volunteer set-up with chest coil again, and multi-slice aortic flow quantifications 
are repeated as before with new set-up.  
 
The scan parameters for the C-PWV are the same as described in Chapter 3.2. The multi-
site acquisition was a breath-hold PC-MRI sequence, with lower temporal and spatial 
resolution than the C-PWV technique. Comparisons of the scan parameters for both PC-
MRI sequences are detailed in Table 6-1. 
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Table 6-1 Phase contrast pulse sequence parameters for C-PWV and MS-PWV  
Parameter (3.0T Siemens) 
Conventional 2-Slice PC Multi-site PC 
Repetition time (ms) 14 22.85 
Echo time (ms) 4.83 1.83 
Field of view (mm) 350 350 
Flip angle 20° 30° 
Slice thickness (mm) 8 6 
Resolution 256 x 256 144x192 
No of segments 3 3 
No of averages 1 1 
Number of phases 128 128 
VENC (cm.sec
-1
) 150 150 
Average scan time 240- 360 sec (4- 6 mins) 20-30 sec 
 
Multiple images of the aorta were acquired in axial oblique orientation from the aortic arch 
(starting at the ascending aorta at the level of the pulmonary bifurcation) and ending at the 
descending aorta (immediately proximal to the renal arteries) using a consistent gap of 3cm 
as shown in 
Figure 6-1 between slices. Image analysis was completed using the same software as the 
previous methodology described in Chapter 3.3.2. The transit-time was calculated for each 
of the flow waves at each location (Figure 6-2) and the slope of these interval times at 
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different regions, along with the distance between slices were used to calculate mean MS-
PWV of the aorta.  
 
Figure 6-1 Multi-site PWV acquisition at different intervals along the aorta. Left 
Image is a FLASH ‘Candy Stick’ View of the aorta a right image is multi-slice waveforms 
for PWV assessment for a YHV 
 
 
Figure 6-2 Interval times (sec) versus distance (m) of each slice position: The inverse 
slope of time and distance represents mean PWV (ms
-1
) value.  
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6.3.3 Statistical Analysis  
Between group differences were calculated using a paired t-test and repeated measures 
ANOVA. Significance was assumed at P < 0.05. 
6.4 Results 
6.4.1 Validation of C-PWV and MS-PWV  
The mean aortic PWV for the YHV was found not to be significant different between C-
PWV and MSPWV techniques (paired t-test, P = 0.14). These PWV ranges are displayed in 
Table 6-2 and Figure 6-3. 
Table 6-2 Mean PWV results: C-PWV and MS-PWV on young healthy volunteers (YHV) and for 
a repeated MS-PWV scan on the same day.  
 C-PWV (ms
-1
) MS-PWV (ms
-1
) Repeated MS-PWV (ms
-1
) 
YHV 4.22 ± 0.6 4.52 ± 0.7 4.82 ± 0.8 
 
Figure 6-3 Means plot with SDs for both PWV techniques, C-PWV and MS-PWV (t-test, P > 
0.05). A repeat scan was also performed with MS-PWV to test its scan to scan variation. No 
significant difference was found between the first MS-PWV and the repeat scan (t-test, P > 0.05)  
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6.4.2 Reproducibility of MS-PWV 
Reproducibility of MS-PWV was examined by repeating the multi-site PC-MRI acquisition 
on the same day. No significant difference was seen between either acquisition (paired t-
test, P =0.24). Bland-Altman and regression analysis were performed to investigate the 
difference between the techniques and linear relationship with each other (C-PWV and MS-
PWV 1, and MS-PWV (1) and MS-PWV (2) as represented in Figure 6-4. A weak 
regression was seen between the C-PWV and MS-PWV (R
2 
=0.04).  
 
 
Figure 6-4 Bland-Altman (95% upper and lower confidence intervals) and regression 
analysis: Where (A), (B): comparing C-PWV and MS-PWV 1, and (C), (D): comparing 
MS-PWV 1 and MS-PWV 2. 
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6.5 Discussion 
In this present study, the performance of MS-PWV, in comparison to the conventional MR-
PWV method, was evaluated in a cohort of YHV. The main findings of this study were (i) 
no significant difference was seen between C-PWV and MS-PWV and (ii) MS-PWV was 
found to be repeatable on a scan to scan basis. 
 
The mean PWV for both groups (C-PWV, MS-PWV) and (MS-PWV 1, MS-PWV2) were 
shown not to be significantly different. The mean C-PWV was slightly lower than the MS-
PWV (4.22 versus 4.52 ms
-1
, P = 0.14). There was high reproducibility seen with MS-PWV 
(R
2
 = 0.66), and no significant change in mean PWV.  
 
The C-PWV provides a higher temporal resolution while the multi-site technique provides 
increased spatial sampling density secondary to more sampling locations along the aorta. 
Kröner et al. (2012) showed by adding more than two slice locations along the aorta, 
increased the accuracy of PWV. The purpose of this study was to compare our MS-PWV 
with the C-PWV, already implemented in clinical research studies (SUMMIT) and to 
investigate if MS-PWV was a viable technique for use in a patient population with PVD 
(Chapter 7).  
 
Reproducibility is an important factor for any new technique with research applications, 
particularly in the case of longitudinal studies. In this case, it is important to know if a 
patient is scanned on a different day with a different set-up, the potential error in set-up will 
not result in a false-positive change in aortic PWV. It has been previously shown that C-
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PWV shows agreement with invasive pressure measurements and can be reproduced with 
high reproducibility (Grotenhuis et al. 2009; Ibrahim et al. 2010) and the results of this 
study show that MS-PWV is a repeatable technique.  
 
The advantages of MS-PWV over a C-PWV include the improvement of PWV accuracy 
from multiple points along the aorta, its reduced acquisition time post-planning, average 12 
minutes for C-PWV versus 4 minutes MS-PWV (6 - 8 acquisition with a 25 second breath-
hold) and increased likelihood of earlier detection of heterogeneous processes such as 
atherosclerotic disease.  
 
A limitation of this work was reproducibility of C-PWV was not evaluated with MS-PWV 
on the second scan. This was due to time restraints of having a long protocol. The total scan 
length for these volunteers was approximately 40 minutes for the first part of the scan and 
15 minutes for the second part. Additionally, the volunteers were given time to leave the 
scanner table before the repeat set-up and localiser and planning sequences had to be 
repeated.  
 
Even though MS-PWV has a shorter acquisition time in comparison to C-PWV; the 
analysis time of multiple image stacks was substantially increased. The lower temporal 
resolution also made the boundaries of the aortic wall more difficult to segment by the 
software so more manual adjustment is was necessary.  
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Another limitation is the lower temporal resolution of the MS-PWV sequence and the 
requirement for a breath-hold during sequence acquisition. We stated earlier in the initial 
validation work (Chapter 4), that lowering the temporal resolution reduces our 
reproducibility compared to a higher temporal resolution image. However, due to the 
acquisition of more sampling points, the error is reduced over multiple sites, although there 
was a slightly higher SD in the MS-PWV than the C-PWV in this healthy volunteer study. 
 
6.6 Summary  
In conclusion, this chapter investigated the use of a breath-hold multi-site approach to 
calculate PWV. MS-PWV was found comparable with C-PWV technique, even on a scan 
to scan basis. No apparent advantages were seen in this YHV population, but possibly with 
increased atheroma burden, a multi-site approach may offer provide better evaluation of 
aortic stiffening, thus allowing a more accurate PWV.  
The following Chapter 7 will examine the MS-PWV in older population and patients with 
known PVD.  
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 CHAPTER 7
Multi-Site Aortic PWV in Peripheral Vascular Disease  
7.1 Introduction  
As previously demonstrated in Chapter 7, CMR can interrogate multiple vessel regions 
within a single examination and provides a non-invasive method of estimating PWV along 
the entire aorta. MS-PWV technique was found to be repeatable and comparable with C-
PWV in a young population. The aim of this chapter is to apply this MS-PWV technique to 
an older population and a patient cohort of PVD, to examine if a multi-site approach may 
be beneficial when there’s an increased likelihood of disturbances to wave reflections and 
increased atheroma burden.  
 
7.2 Study Aims  
The aims of the research presented in this chapter are:   
i. To estimate aortic PWV technique using a multi-site approach in a cohort of YHV, 
(< 40 years), an OPV (> 40 years) and a patient population with clinically diagnosed 
PVD. 
ii. To further investigate aortic PWV ranges in relation to disease severity of PVD   
iii. To investigate the relationship with LV function and disease severity of PVD  
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7.3 Methods 
7.3.1 Demographics and Baseline Characteristics 
For this study, a cohort of YHV, (as previously described in Chapter 7), OPV and a patient 
cohort with clinically diagnosed PVD were recruited (n = 70 in total). All MRI 
examinations were performed with setup as described in Chapter 3. A breakdown of the 
demographics of each of the groups is shown in Figure 7-1. 
 
Table 7-1 Description of cohorts YHV, OPV and PVD 
CMR data YHV OPV PVD 
Sample Size 22 22 26 
Age 29 ± 6 61.1 ± 6 72 ± 7 
Gender 10M:12F 10M: 12F 17M: 9F 
 
The PVD patients were also classified into mild/moderate and severe after assessment of a 
peripheral angiogram by an experienced radiologist. This division of PVD severity is 
displayed in Table 7-2.  
 
Table 7-2 Breakdown of PVD patients into disease severity for MS-PWV assessment 
CMR data Mild/ Moderate PVD Severe PVD ANOVA 
Sample Size 17 9 NA 
Age 63 ± 10 72 ± 7 NS, P=0.69 
Gender 11M: 6F 6M: 3F NA 
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7.3.2 Image Acquisition and Analysis 
 
MRI study protocol was designed to assess cardiac and aortic function (as described in 
Chapter 3). Aortic PWV was estimated via the MS-PWV method and scan parameters are 
outlined in Chapter 6. The YHV results (MS-PWV and LV) from the previous chapter are 
continued in this chapter. OPV received full cardiac, WBA and MS-PWV assessment, as 
defined in Chapter 4.  
 
PVD patients, as defined from clinical diagnosis, were recruited from an ongoing study and 
received a similar MRI protocol as SUMMIT study (Chapter 5), assessing LV function, 
WBA and MS-PWV.  
 
7.3.3 Statistical Analysis  
Descriptive statistics was used for the analysis of the demographic of the cohorts with data 
expressed as mean ± SD. Between group differences were calculated using an analysis of 
variance (ANOVA) test, with LSD post-hoc adjustment applied for multi-comparisons with 
both PWV and LV function. Significance was assumed at P < 0.05. 
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7.4 Results 
7.4.1 MS-PWV between Groups  
The calculated mean MRI PWV for the YHV cohort (4.5 ± 0.7 ms
-1
) was significantly 
slower relative to the mean PWV for the OPV cohort (6.5 ± 1.5 ms
-1
, P = 0.003) and the 
PVD cohort (8.6 ± 3.1 ms
-1
, P = 0.002) as shown in Table 7-3. A box-plot of the MS-PWV 
from each of the cohorts is shown in Figure 7-1, ANOVA test with LSD correction applied.  
Table 7-3 Aortic PWV between cohorts: Mean PWV was found to be significantly different 
between YHV, OHV, PVD (ANOVA, *P < 0.001). 
CMR data 
Group 1 
YHV 
Group 2 
OPV 
Group 3 
PVD 
ANOVA 
Sig. 
PWV (ms
-1
) 4.5 ± 0.7, n=22 6.5  ± 1.5, n=22 8.6 ± 3.1, n=26 *P < 0.001 
 
 
Figure 7-1 Box-plot of aortic PWV between cohorts: Mean PWV was found to be 
significantly different between YHV, OHV, PVD (ANOVA, P < 0.001).  
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7.4.2 MS-PWV and Peripheral Vascular Disease  
PVD patients were divided into clinical severity as verified by MRA of the peripheral 
vasculature. Mean PWV was significantly slower in both the mild/moderate PVD patients 
compared to the severe PVD group (7.6 ms
-1 
versus 10.8 ms
-1
, P = 0.02). The division of 
the groups can be seen in Table 7-4.  
Table 7-4 Aortic PWV and PVD severity: Mean PWV was found to be significantly different 
between different classifications of PVD (ANOVA, *P = 0.02). 
CMR data Mild/ Moderate PVD Severe PVD 
ANOVA 
Sig. 
PWV (ms
-1
) 7.6 ± 2.5, n = 17 10.8 ± 3.4, n = 9 *P = 0.02 
 
 
Figure 7-2 Box-plot of Aortic PWV and PVD severity: Mean PWV was found to be 
significantly different between mild/moderate versus severe PVD (ANOVA, *P = 0.02).  
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7.4.3 Left Ventricle Function between Groups  
The LV analysis was completed for all YHV and OPV. Four patients from PVD group 
were excluded from the analysis due to poor image quality (n = 3) and uncompleted scan (n 
= 1). The results for the final participants are shown in the Table 7-5 below.  
 
The means and SD are presented in Table 7-5 for each of the LV parameters. The ANOVA 
revealed a significant difference between the SV (P = 0.002). LSD post-hoc analysis 
revealed that for SV was significantly lower in PVD than in YHV and OPV (P = 0.001 and 
P = 0.013 respectively). 
 
EDV also showed a trend towards significance (P = 0.06), with LSD post-hoc analysis 
revealing that EDV was significantly higher in YHV in comparison to PVD patients (P = 
0.02). 
 
Table 7-5 LV function between groups: Mean PWV was found to be significantly different 
between different classifications of PVD (ANOVA, *P < 0.05). 
CMR data  
YHV  
(n = 22) 
OPV 
(n = 22) 
PVD 
(n=22) 
ANOVA  
Sig. 
EF (%) 66.1 ± 6.1 65.5 ± 6.8 64.8 ± 8.6 NS, P = 0.86  
EDV-N (ml) 80.5 ± 8.6 77.6 ± 13.7 71.1 ± 14.0 NS, P = 0.06 
ESV-N (ml) 27.3 ±6.3 27.2 ± 8.3 26.2 ± 11.3 NS, P = 0.90 
SV-N (ml) 53.2 ± 7.4 50.4 ± 7.9 44.9 ± 5.8 * P = 0.002 
LVM-N (gm
-2
) 61.6 ± 10.7 56.3 ± 11.1 61.8 ± 9.7 NS, P = 0.16 
Abbreviations: EDV-N: Normalised End Diastolic Volume, ESV-N: Normalised End Systolic Volume, SV-
N: Normalised Stroke Volume, LVM-N: Normalised Left Ventricular Mass. 
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7.4.4 LV Function and Peripheral Vascular Disease  
 
The LV analysis was also divided into grades of severity. The results for the PVD patients 
are shown in the Table 7-6 below. The means and SDs are presented in Table 7-6 for each 
of the LV parameters. The ANOVA revealed no significant difference between the 
different severity grades of PVD (P > 0.05).  
 
Table 7-6 LV function and PVD severity: Mean PWV was found to not to be significantly 
different between different classifications of PVD (ANOVA, P > 0.05). 
CMR data  
Mild/ Moderate PVD  
(n = 17) 
 Severe PVD 
(n = 6) 
ANOVA  
Sig. 
EF (%) 64.8 ± 8.8 62.8 ± 8.6 NS, P = 0.59  
EDV-N (ml) 71.8 ± 9.4 68.3 ± 12.8 NS, P = 0.85 
ESV-N (ml) 26.8 ± 12.2 26.5 ± 11.4 NS, P = 0.93 
SV-N (ml) 44.9 ± 5.8 41.8 ± 6.9 NS, P =0.18 
LVM-N (gm
-2
) 61.4 ± 9.2 61.0 ± 12.9 NS, P = 0.72 
Abbreviations: EDV-N: Normalised End Diastolic Volume, ESV-N: Normalised End Systolic Volume, SV-
N: Normalised Stroke Volume, LVM-N: Normalised Left Ventricular Mass. 
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7.5 Discussion  
 
Following on from the previous study, this study evaluated MS-PWV in three different 
cohorts; YHV, OPV and PVD. The main findings of this study show (i) mean MS-PWV 
was significantly different across the three cohorts, YHV, OPV and PVD, (ii) MS-PWV 
correlated with age and PVD disease severity and (iii) stroke volume was reduced in PVD 
compared to YHV and OPV.  
 
Both degenerative stiffness and arteriosclerosis of the arterial beds tend to coexist resulting 
in a progressive, diffuse and age-related disease process of vascular beds (Cavalcante et al. 
2011). As previously mentioned in 1.1, the origins of the SMCs of the basal, ascending and 
the descending aorta have been shown to have regional diversity. This may contribute to 
the susceptibility of site-localisation of vascular disease, and promote heterogeneous 
arterial stiffness (Cheung et al. 2012).  
 
The mean PWV differed between the YHV, OPV, and with PVD (4.5 ms
-1
, 6.5 ms
-1
 and 8.6 
ms
-1
, P < 0.001) indicating that age and disease was a distinguishable factor. The PVD 
patients were divided into three groups by disease severity after MR angiographic data of 
the peripheral vessels. In terms of disease severity, MS-PWV showed diagnostic capability 
to differentiate between mild/ moderate PVD from severe PVD burden (7.6 ms
-1
 versus 
10.8 ms
-1
, P = 0.02). However, it was unable to distinguish mild/ moderate burden, as the 
mild PVD phenotype in this group, and the extent of the disease heterogeneity in this group 
(4.5 ms
-1
and 6.5 ms
-1
, P > 0.05).   
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As this was a novel exploration, and there are no prior MR-PWV values for a PVD cohort, 
the MS-PWV technique was compared to LV function, an established clinical reference. In 
the PVD cohort, this study showed a marked decrease in SV and increase in EDV 
compared to the healthy participants. Interestingly, no significant changes in LVM were 
evident between PVD or in relation to increasing severity and overall burden. This may 
suggest that even though these patients had elevated arterial stiffness, structural 
remodelling of the LV had not significantly changed. This may suggest that there may be 
potential role for aortic PWV within this population, evaluating overall cardiovascular 
burden before the onset of cardiac dysfunction. 
 
Limitations of Study 
A limitation of the study is the absence of an age matched control groups. The OPV were 
participants in the TASCFORCE study (as described in Preface), and the mean age was 
lower than the PVD cohort. Ideally, this group would have been age and gender matched to 
the patent population. Secondly, this study included the use of a breath-hold PC-MRI 
acquisition. However, some PVD patients found it difficult to hold their breath in 
comparison to the YHV and OPV, resulting in breathing artefacts on several image sets. It 
also should be noted that PVD patients are more commonly classified using the ankle 
brachial index (ABI). As we did not have this data, we used peripheral angiograms and 
clinical report to classify the patients, which may be more subjective than ABI.   
Finally, in this study we estimated the mean PWV over the entire aorta using different sites. 
As this was a multi-site acquisition, we could of also investigated PWV in different aortic 
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regions such as the ascending, distal or proximal aorta. This would have provided analysis 
of how arterial stiffness varies over the aorta in both a healthy population and a PVD 
cohort. This work will be further expanded in future work for this cohort.  
 
7.6 Conclusion 
In conclusion, this study utilised a MS-PWV technique in an ageing and PVD population. 
Atherosclerosis is a heterogeneous pathophysiological process occurring in various focal 
points and different vascular beds; to which arterial stiffening may also vary along the 
aortic length. Sampling from multiple points along the aorta may provide a more sensitive 
measure of aortic stiffness, particularly in the earlier stages of disease.  
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 CHAPTER 8
Discussion and Further Work  
 
8.1 Aim of Thesis 
The aim of this thesis was to examine the use of MR-PWV (i) to investigate whether PWV 
can be used as a surrogate MRI marker of macrovascular disease in a heterogeneous 
population with and without CVD, and (ii) whether these markers can provide greater risk 
prediction of CVD risk compared to established MRI parameters of ventricular function. 
8.2 Key Findings  
In summary, the studies in this thesis show that MR-PWV is affected by both the extent and 
severity of atherosclerotic burden and CVD.  
 MR-PWV when applied to a complicated T2DM population with and without 
symptomatic CVD; PWV yields an important distinction between the CVD groups 
which was not apparent with other parameters including LVM. In contrast, PWV 
was unable to distinguish between T2DM populations before the onset of 
symptomatic CVD.   
 A developed technique, MS-PWV, has shown to be comparable with the C-PWV 
technique in a cohort of YHV. 
 In cohorts of YHV, OPV and PVD, MS-PWV found a significant difference in 
mean PWV in a between an ageing population and patients with symptomatic PVD. 
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 Using MRA, PVD was classified into a score system where the degree of severity 
was attributed; mild, moderate and severe, MS-PWV was significantly higher in 
severe PVD compared to mild or moderate PVD. However, it was unable to 
distinguish between mild onset and moderate PVD burden. 
 
This thesis provides a novel insight into the process of arterial stiffening though a non-
invasive MRI assessment of arterial stiffness and subsequent cardiovascular health 
throughout different disease cohorts. It differs from current published work by examining 
MR-PWV in a heterogeneous T2DM and CVD population, whilst previous studies have 
examined either T2DM or CVD patients in isolation.  
Secondly, a multi-site arterial assessment approach was used to determine aortic PWV in a 
PVD population, a novel application. Modification of the conventional MR-PWV imaging 
protocols allowed to account for site variation along the aorta, a known phenomenon of 
atherosclerosis.   
8.2.1 Clinical Implications of MRI Derived Aortic PWV   
In order to become a useful CVD screening tool, MR-PWV ideally needs to be able to 
predicate major macro and microvascular disease in asymptomatic patients, where such 
values supplement existing risk scores models (Greenland et al. 2010). The techniques 
discussed in this thesis have shown value in detecting symptomatic CVD. However, it 
cannot be determined if MR-PWV has the potential to be implemented as a screening tool 
for asymptomatic population without sufficient longitudinal data.  
To this need, new evidence is beginning to emerge from larger studies such as the multi-
ethnic study of atherosclerosis (MESA). This is the first longitudinal study to used MR-
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PWV as a screening tool, covering a 10 year period with 226 participants (Liu et al. 2012). 
Also, an even larger subgroup of the Dallas Heart Study (DHS), consisting of 2122 
participants underwent CMR measures of arterial stiffness, to which it was found to have 
an association with adverse cardiovascular events (Maroules et al. 2014).  
 
In conclusion, taken together with the high cost, and limited availability, MR-PWV is 
mainly confined to a research setting, and may not be applicable for routine CVD risk 
monitoring in the population. For MR-PWV to gain clinical diagnostic value, it is necessary 
for it to gain increasing evidence in larger, longitudinal studies and thus providing a 
definable prognostic range for normal and abnormal arterial stiffness. Alternatively, it may 
serve as a suitable target for pharmaceutical interventions studies such as the lipid lowering 
drugs statins. In the meantime, what remains to be shown is whether vascular stiffness has 
potential to be a therapeutic target. It can be argued, results from MESA and DHS and 
forthcoming studies may provide the evidence base behind the widespread adaptation and 
value of this technique. 
8.3 Limitations 
Commercial Software for Estimating PWV 
A major limitation inhibiting the routine use of MR-PWV, is the lack of a PWV 
commercially software package. The majority of the studies to date have either used a flow 
quantification software analysis programme, estimating transit times manually or an ‘in-
house’ developed software. The second difficulty is defining a ‘standardised’ approach for 
image acquisition for calculating PWV. This thesis has only investigated through-plane 2D 
PC-MRI, however recent work from Leiden University have derived PWV from an in-
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plane PC-MRI acquisition, stating that it showed a stronger correlation with invasive 
pressure measurements (Westenberg et al. 2012).  
 
Research based MRI Sequences 
The studies within this thesis were confined to using 2D PC-MRI for flow quantification as 
we were restricted to commercial sequences that were readily available in on the scanner. 
However, there are a plethora of other MRI techniques that could have been applied such as 
Fourier velocity encoding (FVE) motion-mode (M-mode) imaging and 4D PC-MRI 
methods (Markl et al. 2010).   
For instance, the advantage of using FVE M-mode imaging is its high temporal resolution 
(~ 3 to 5 ms, in comparison to 2D-PC-MRI at ~ 10 – 30 ms). It is acquired through a 
pencil-beam acquisition and is therefore restricted to research sites as its not commercially 
available technique (Taviani et al. 2010).  
 
Availability and Resources 
Although, good accuracy and direct aortic flow measures are achievable with MR-PWV, it 
presents other difficulties in a clinical setting. MRI scans are generally associated with high 
cost, poor accessibility and have many restrictions on patient’s eligibility (e.g. pacemakers, 
metal implants). Therefore, predominately restricting arterial stiffness derived by MRI to a 
research setting.    
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8.4 Future Work 
In Chapter 5, we determined MR-PWV for different cohorts of patients with and without 
CVD as part of a multi-centre SUMMIT study. This same cohort of patients also received 
vascular function tests in the vascular and inflammatory unit, including CF-PWV. 
Preliminary analysis was performed between both PWV techniques and interestingly 
showed good correlation in healthy control cohorts, but weaker correlation in the CVD 
patients. One hypothesis for this difference may potentially be due to the error in distance 
measurement between the two sites. With ageing, the aorta is thought to become elongated 
and more tortuous (Sugawara et al. 2008).  Additionally, in the case of vessel occlusion, 
there is an increase likelihood of collateral vessels that shunt blood supply around a 
blockage in the CVD cohorts. Both of these factors may in theory contribute to extended 
distance between the carotid and femoral sites, not accountable with the traditional tape 
measure approximation. With the aid of whole body MRA, these vessels are easily 
identifiable and correspondingly, a definite distance between the sites can be defined. 
Further analysis will include estimating this distance discrepancy and examining its 
outcome to the overall CF-PWV value. 
 
Other Haemodynamic Factors 
As discussed previously, haemodynamic factors are a strong predictor of the early stages of 
disease progression. This thesis focused on estimation of PWV through the analysis of flow 
quantification at various sites along the aorta. While this is a clinically validated 
measurement, there may be further data of diagnostic value currently uncovered, for 
example flow patterns, forward and backward flow and wave reflections that may provide 
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further insight into the pathophysiological processes of altered PWV. It would be 
interesting if we could further understand these wave characteristics and investigate the 
relevance to disease pathology.  
 
General Developments in Flow MRI  
Emerging techniques such as 4D flow, in which spatial encoding is combined with 3D 
velocity encoded PC-MRI, is still developing in the field of MR research (Markl, 
Frydrychowicz, et al. 2012). It provides a comprehensive analysis of blood flow dynamics 
using a full volumetric region of interest and is not confined to standardising slice 
placement in patients with tortuous vessels, and allows multiple waveforms to be sampled 
at the same time (Figure 8-1). Likewise, it provides the opportunity of deriving other 
clinically interesting haemodynamic parameters, including WSS, pressure gradients across 
stenosis and other flow related parameters (Goubergrits et al. 2014; Markl, Wallis, et al. 
2012). In the future, these techniques may evolve into additional diagnostic information 
that may contribute to earlier detection of disease or assist with surgical planning decisions.   
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Figure 8-1 4D phase contrast MRI: The assessment of PWV of a healthy volunteer is shown in 3 
out of 20 cardiac phases with delay time 125 ms, 251 ms and 630 ms. The velocity data is 
highlighted using velocity vectors and overlaid on the anatomical data (greyscale). As reproduced 
from (Wentland et al. 2014).  
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8.5 Conclusion 
 
Aortic PWV, as derived from MRI is associated with both the extent and severity of 
atherosclerosis and CVD. PWV was able to distinguish symptomatic CVD, which was not 
apparent in cardiac function parameters. In order for MR-PWV to be used as a screening 
tool, it needs to be able to predicate major macro and micro-vascular disease in 
asymptomatic patients. Future work from risk prediction and longitudinal studies is 
necessary to evaluate the prognostic value of MR-PWV.  
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APPENDIX A 
MRI Study Protocols  
(i) Summit Study MRI protocol 
  
165 
 
(ii) Healthy Volunteer Multi-site PWV MRI Protocol  
 
 
(iii) Older Healthy Population (TASCFORCE) MRI Protocol 
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(iv) Peripheral Vascular Disease Study MRI Protocol  
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APPENDIX B 
Conference Presentations   
 DB Cassidy, SJ Gandy, F Khan, P Martin, RS Nicholas, JG Houston, ‘Can Magnetic 
Resonance Pulse Wave Velocity Measurements Characterise Aortic Cardiovascular 
Disease?’,  International Conference of Medical Physics, Oral Presentation, Brighton, 
September 2013. 
 DB Cassidy, SJ Gandy, S Duce, S Matthew, P Martin, RS Nicholas, JG Houston , ‘The 
Fatty Heart: CMRI Study of Diabetes and Cardiovascular Disease’, Oral Presentation,  
International Conference of Medical Physics, Brighton, September 2013. 
 DB Cassidy, SJ Gandy, S Duce, F Khan, P Martin, RS Nicholas, JG Houston, 
‘Investigating the Role of Epicardial Fat as an Imaging Biomarker in Type-2 Diabetes’, 
Poster, International Union of Physiological Sciences, Poster Presentation, 
Birmingham, July 2013. 
 DB Cassidy, SJ Gandy, S Duce, S Matthew, P Martin, RS Nicholas, JG Houston, 
‘Diabetes and Myocardial Fat in the Paradigm of Cardiovascular Disease’, Oral and 
Poster Presentation, UK Radiology Congress, Liverpool, June 2013.  
 DB Cassidy, SJ Gandy, S Duce, S Matthew, P Martin, RS Nicholas, JG Houston 
Preliminary Investigation into the Benefits of Imaging Myocardial Fat’, Scottish Heart 
and Arterial Risk Prevention, Oral and Poster Presentation, Dunkeld, November 2012. 
 DB Cassidy, SJ Gandy, P Martin, RS Nicholas, JG Houston ‘Investigation of Magnetic 
Resonance Pulse Wave Velocity Measurements: Can it Characterise Aortic 
Cardiovascular Disease?’, UKRC abstract, Oral Presentation, Manchester, June 2012. 
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Pulse Wave Velocity Measurements Characterise Aortic Cardiovascular Disease?’ 
Scottish Cardiovascular Forum, Oral Presentation, Dundee, Feb 2012. 
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